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ABSTRACT 
Ocular drug delivery is one of the most challenging fields of pharmaceutical research. 
They are generally employed to overcome the static (different layers of cornea, sclera, 
and retina including blood aqueous and blood-retinal barriers) and dynamic barriers 
(choroidal and conjunctival blood flow, lymphatic clearance, and tear dilution) of the 
eye. Ophthalmic formulations must be sterile, and the biomaterials used in the 
preparation of pharmaceutical systems completely compatible and extremely well 
tolerated by ocular tissues. The location of the target tissue in the eye will determine the 
route of administration. Ophthalmic administration systems are intended for topical, 
intraocular and periocular administration. In this review we describe the main 
pharmaceutical nano- and microsystems currently under study to administrate drugs in 
the eye, covering microparticles, nanoparticles, liposomes, microemulsions, niosomes 
and dendrimers. We have performed the corresponding revision of the published 
scientific literature always emphasizing the technological aspects. The review discusses 
also the biomaterials used in the preparation of the nano and microsystems of 
ophthalmic drug delivery, fabrication techniques, therapeutic significances, and future 
possibilities in the field. 
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ABBREVIATIONS 
ACV Acyclovir  
ACA Alkyl cyanoacrylate 
ACZ Acetazolamide 
AIDS Acquired immune deficiency syndrome 
AmpB Amphotericine B 
ARMD Age-realted macular edema 
AS-ODNs Antisense-oligodesoxinucleotide 
AUC Area under the curve 
BSA Bovine serum albumin 
BSS Balanced saline solution 
C24 Poly-24-oxyethylene cholesteryl ether  
CH Sodium cholate 
Cht Cholesterol 
Cmax Maximal concentration 
CMC carboxymethyl cellulose 
CMV Cytomegalovirus 
CNV Choroidal neovascularization 
CSN Chitosan 
CyS Cyclosporines 
Cy A Cyclosporine A 
DDBA18 Dioctadecyl-dimethyl-ammonium bromide 
DMPC 1,2-dimyristoyl-sn-glycerol-3 phosphocholine 
DMPE Di-myristoyl-phosphatidyl-ethanolamine 
DNA Deoxyribonucleic acid 
DOPS 2-dioleoyl-sn-glycerol-3-phospho-L-serine 
DOTAP 1,2-dioleoyl-3-trimethylammonium-propane 
DP Dicetylphosphate 
DPPC Dipalmitoyl phosphatidylcholine 
DPPS Dipalmitoylphosphatidylserine 
DPTs Dendritic polyguanidilyated translocators 
DR Diabetic retinopathy 
DSEP Polyethylene glycol-distearoyl ethyl phosphocoline 
DSPC Distearoyl phosphatidylcholine 
DSPE 1,2-Distearoyl-sn-glycero-3 phosphatidylethanolamine 
Dx Dexamethasone 
EE Encapsulation efficiency 
EGFP Green fluorescent protein 
EMA European medicines agency 
FDA Food and Drug Administration 
GCV Ganciclovir 
GDNF Glial-cell-line-derived neurothropic factor 
GSH Gluthatione 
HA Hyaluronic acid 
HEMA 2-hydroxyethyl methacrylate 
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HET-CAM Hen’s egg test-chorioallantoic membrane 
HPMC Hydroxypropyl methyl cellulose 
HSV-1 Herpes simplex virus type 1 
HUVECs Human umbilical vein endothelial cells 
IgG Immunoglobulin G 
IOBA-NHC Instituto de Oftalmobiología Aplicada- Normal Human Conjunctiva 
IOP Intracoular pressure 
K5 Plasminogen kringle 
LC Liquid crystalline 
LCT Lecithin 
LPS lipopolysaccharide 
LUVs Large unillamelar vesicles 
ME Microemulsion 
MLV Multillamelar vesicle 
MPEG-2000-DSPE 1,2-Distearoyl-sn-glycero-3 phosphatidylethanolamine-n-
((maleneimide/polyethyleneglycol)-2000) 
MP Microparticle 
NHC Normal human conjunctiva 
NP Nanoparticle 
NTX Naltrexone hydrochloride 
O/O Oil-in-oil 
O/W Oil-in-water 
OND Oligonucleotide 
PACA Poly(alkyl cyanoacrylate) 
PAMAM Polyamidoamine 
PBS Phosphate buffer solution 
PC Phosphatidylcholine 
PCL Polycaprolactone 
PEG Poly(ethylene gycol) 
PEI Polyethylenimine 
PGE2 Prostaglandine E2 
PLA Polylactic acid 
PGA Polyglycolic acid 
PLGA Poly(lactic-co-glycolic) acid 
PMA Polymethacrylic acid 
PPI Polyethylenimide 
PS Phosphatidilserine 
PS-OND Phosphorothioate oligonucleotide 
PVA Polyvinil alcohol 
PVR Proliferative vitreoretinopathy 
RA Retinoic acid 
REV Reverse phase evaporation 
RGC Retinal ganglion cells 
Rh Rhodamine 
RNA Ribonucleic acid 
RPE Retinal pigmented epithelium 
SA Stearylamine 
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SLA sulfacetamide sodium  
SLPN Solid lipid nanoparticles 
SUV Small unillamelar vesicle 
TA Triamcinolone acetonide 
TBUT Tear break-up time 
TGF-B2 Transforming growth factor beta 2 
TRD Tractional retinal detachment 
VEGF Vascular endothelial growth factor 
VIP Vasointestinal active peptide 
W/O/W Water-in-oil-in-water 
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1.- INTRODUCCION 
1.1. Nano- and microsystems for ophthalmic administration 
Ocular disorders treatment can benefit from the use of ophthalmic formulations based 
on nano- and microsystems. In the case of diseases affecting the ocular surface or if the 
drug has to reach the anterior segment of the eye, the topical administration is the 
preferred route. The conventional ophthalmic preparations used in this case (eye drops) 
show as great inconvenient the short residence time of formulations on the ocular 
surface, due to drainage of solution, tear turnover, its dilution by lacrimation and the 
low corneal permeability of most of the drugs. All these limitations cause poor ocular 
bioavailability and it is estimated that approximately only the 5% of instilled drug 
would reach the target site [1].  
 The use of pharmaceutical systems able to increase the retention time of drugs on the 
ocular surface, and in some cases to enhance the corneal transport, are intended to 
increase the drug bioavailability after topical administration, reducing the number of 
applications per day and increasing the patients’ compliance. Colloidal systems as 
liposomes, nanoparticles, niosomes and microemulsions have been developed to 
increase ocular drug bioavailability. Most of them are also useful for delivering the drug 
in the target site. Most recently, dendrimers have emerged in the ophthalmic field to 
augment the poor bioavailability of drugs applied on the surface of the eye exploring 
their ability to interact with the mucins of the ocular surface. The specific structure of 
these biopolymers makes them also useful for targeting. Furthermore, they are one of 
the most promising non-viral transfection agents explored in gene therapy. 
Regarding the pathologies affecting the posterior segment of the eye, the objective is to 
deliver the drug in the vicinity of the target tissue. For these pathologies the use of 
topical administration results ineffective and systemically administered drugs cannot 
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achieve therapeutic drug concentrations in the posterior segment of the eye due to the 
blood-aqueous and blood-retinal barriers. The more suitable route is then the intraocular 
injection of the active substance, dissolved or suspended in a vehicle, or its periocular 
injection if the drug can cross the different tissues to reach the back of the eye. The 
main lack-point of these administrations is the need of repeated injections to achieve 
therapeutic drug levels for prolonged periods of time, which is generally necessary to 
treat the chronic pathologies affecting the posterior segment. In that sense intraocular 
and periocular implants and microparticulate delivery systems may address the risk of 
side effects associated with repeated injections as they are able to release the drug for 
long periods of time. At this level, nanosystems are useful tools to protect the active 
substance of the external environment and to target the drug to ocular tissues. 
Ocular drug delivery is one of the most challenging fields of pharmaceutical research. It 
is not only necessary to overcome the static (different layers of cornea, sclera, and retina 
including blood aqueous and blood-retinal barriers) and dynamic barriers (choroidal and 
conjunctival blood flow, lymphatic clearance, and tear dilution) protecting the eye, but 
they must also fulfil more restricted specifications than the devices designed for other 
administration routes. The drug delivery systems prepared must be sterile and the 
biomaterials used in the preparation of the systems must be completely compatible and 
extremely well tolerated by ocular tissues.  
In this review we describe the main nano- and microsystems under study to administrate 
drugs in the eye, covering microparticles, nanoparticles, liposomes, microemulsions, 
niosomes and dendrimers (figure 1). We have performed the corresponding revision of 
the published scientific literature published during the last decades always emphasizing 
the technological aspects. The review discusses also the biomaterials used in the 
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preparation of nano- and microsystems for ophthalmic administration, fabrication 
techniques, therapeutic significances and future possibilities in the field. 
 
1.1.1. Microparticles  
Microparticles (MPs) are solid drug carriers with diameter of 1 to 1000 µm, capable to 
provide sustained and controlled release of the loaded active agents, while the non-
released substance is protected from degradation and physiological clearance. A large 
variety of active compounds have been encapsulated in microparticles for ophthalmic 
administration, mainly for intraocular drug delivery. The main advantage of these 
formulations is that they can release the drug over the time with one single 
administration, having the same effect than multiple injections. These therapeutic 
systems are usually prepared with a polymer or mixture of polymers and can include 
one or more active substances. By physical structure, microparticles are classified in 
microcapsules and microspheres. Microcapsules are constituted by a drug core, which is 
surrounded by a polymer layer (reservoir structure). Conversely, in the microspheres the 
drug is dispersed through the polymeric network (matrix structure) [2]. 
The main advantage of microspheres over conventional systems for ocular drug delivery 
is that they are able to increase the efficiency of drug delivery by improving the release 
profile and also reduce drug toxicity. Furthermore they can be injected as suspension 
using conventional needles (27-34G) so no surgery is needed. Recent studies have 
demonstrated that microparticles tend to aggregate once injected in the vitreous cavity, 
behaving as an in situ forming implant [3]. The size of microparticles seems to be 
advantageous also for periocular administration. After injection, microparticles are 
retained in the administration site proximities where they can progressively release the 
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loaded actives, differently from smaller particles (nanoparticles) that are mainly cleared 
by the systemic and lymphatic system [4]. 
 
1.1.2. Nanoparticles 
Nanoparticles (NPs) are defined as solid, submicron-sized drug carriers with diameters 
ranging from 1 to 1000 nm [5]. Similarly to microparticles, depending on their 
structure, NPs can be subdivided into nanospheres and nanocapsules. Nanospheres are 
constituted of a dense solid polymeric network with a matrix type structure, in which 
the drug can be either adsorbed on the particle surface or encapsulated within the 
particle. Nanocapsules are small reservoirs consisting of an inner liquid core, where the 
active substance is usually dissolved, surrounded by a polymeric membrane. In 
nanocapsules the active substance can also be adsorbed on the capsule surface.  
Solid lipid nanoparticles (SLNPs) were developed as an alternative to colloidal drug 
delivery systems [6] (lipid emulsions, liposomes and polymeric NPs).  Their structure 
consists of a solid lipid core and an amphiphilic surfactant as an outer shell. The 
presence of these compounds allows the incorporation of lipophilic and hydrophilic 
active ingredients [7]. 
Although the potential of big nanoparticles to sustain the delivery of drugs has been 
shown, microparticles give better results due to the substantial difference of size. 
However, the smaller size of nanoparticles makes them suitable to be taken up by cells, 
for example retinal pigmented epithelium cells (RPE). This fact reveals the utility of 
these systems to treat retinal disorders. Nanoparticles seem to be more useful for 
targeting specific molecules of genetic material into the cells than for sustaining the 
delivery of drugs [8-10].  
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Of special interest is the use of bioadhesive NPs to administrate drugs on the ocular 
surface. Their size does not induce patients’ discomfort and allows them an intimate 
contact with ocular mucins, increasing the retention time of the loaded compounds and 
also improving their corneal penetration [11,12]. 
 
1.1.3. Liposomes 
Liposomes are spherical vesicles composed of an aqueous core enclosed by concentric 
phospholipid bilayers. They are spontaneously formed when phospholipids, which have 
an amphiphilic nature, are dispersed in aqueous medium [13]. The size of liposomes is 
in the range from 10 nm to 10 µm. According to their size and the number of lipid 
bilayers, liposomes are classified into small unillamelar vesicles (SUVs), large 
unillamelar vesicles (LUVs) and multillamelar vesicles (MLVs) if more than one 
bilayer is present (Table 1) [14,15].  
The effectiveness of liposomes as drug delivery systems depends on many factors such 
as the type of lipid employed, size and surface charge of liposomes, characteristics of 
the therapeutic agent and the properties of the definitive liposomal formulation 
developed [16-19]. Liposomes present the advantage of encapsulating both lipophilic 
and hydrophilic molecules. Hydrophilic drugs are entrapped in the aqueous core while 
lipophilic compounds are incorporated in the lipid bilayers [16]. 
Liposomes are considered as promising nanocarriers for ocular administration because 
they are biocompatible, biodegradable and relatively non-toxic. They have received 
considerable attention as ocular drug delivery systems owing to their ability to increase 
the drug residence time on the ocular surface and hence its corneal penetration, 
especially the positively charged liposomes, able to totally cover the ocular surface once 
instilled [20]. Related to intraocular route, liposomes have demonstrated to protect and 
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increase the half-life of fragile active substances avoiding repetitive administrations to 
achieve therapeutic levels in the site of action [21,22]. In the case of intravitreal 
administration, liposomes have demonstrated to be useful in relatively long-term release 
of lipidic pro-drugs [23-25]. Liposomes have been already used in the ophthalmic 
clinical practice[26]. 
Positively-charged (cationic) liposomes have high efficiency for entrapping DNA or 
RNA, due to electrostatic interactions [27-29]. These complexes formed by DNA and 
positively charged liposomes are called lipoplexes and they are used frequently as gen 
carriers to treat ocular pathologies [30,31].  
 
1.1.4. Microemulsions and niosomes 
Microemulsions (MEs) are pharmaceutical systems composed of an oily phase, an 
aqueous phase and a combination of surfactant and co-surfactant at appropriate ratios to 
stabilize the system. ME are an attractive alternative to conventional topical 
formulations since they are thermodynamically stable systems, can be easily prepared 
and sterilized, and present the advantage to incorporate water-soluble and lipophilic 
drugs. Moreover, the surfactants can act as penetration enhancers to increase the drug 
permeability across the cornea. In addition, MEs usually are low viscosity systems with 
a Newtonian behavior, low surface tension values and transparent appearance because 
the nano-size drop (<150 nm) of the dispersed phase. As a result, ME allow an adequate 
mixture with tears and also guarantee a good spreading onto the ocular surface. Thus, 
ME can be administered as eye drops and results in a high patient’s compliance [32-37]. 
Niosomes are formed from the self-assembly of non-ionic amphiphilic compounds in 
aqueous media resulting in bilayer vesicles of size 10-0.5 µm. These relatively new 
systems are interesting for ocular drug delivery. They have some of the advantages of 
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liposomes, because of their ability to entrap both hydrophilic and lipophilic actives 
either in an aqueous layer or in vesicular membrane, but with the improvement of a 
better chemical stability. Niosomes also possess some similarities with microemulsions, 
because of their surfactant composition, able to increase the drug permeability through 
the corneal tissue [38]. Various studies have demonstrated their ability to increase the 
bioavailability of antihypertensive and opioid antagonist drugs, among others, after 
instillation [39-41], due to permeation enhancement behaviour. Other possible reasons 
are the better spreading ability of niosomes on the lipophilic corneal surface and 
increased viscosity compared with drug solutions [42]. 
 
1.1.5. Dendrimers 
Dendrimers are new polymers with a high potential in drug delivery [43-46]. The term 
‘dendrimer’ arises from the Greek dendron, meaning ‘tree’, and meros meaning ‘part’. 
It graphically describes the structure of this class of synthetic macromolecules that have 
highly branched, three-dimensional features that resemble the architecture of a tree [43]. 
Despite their large molecular size (5,000-500,000 g/mol), dendrimers are structurally 
well-defined and have low polydispersity. A typical dendrimer consists of three main 
structural components: (i) a multifunctional central core, (ii) branched units and (iii) 
surface groups [47,48]. The branched units are organised in layers called 
‘‘generations’’, and represent the repeating monomer unit of these macromolecules 
[43]. Generally the number of generations is represented as a digit preceded by the 
capital letter “G” (i.e. G2: generation 2). On a molecular level the dendritic branching 
results in semi-globular to globular structures of a few nanometres of diameter with a 
high density of functionalities on the surface [49]. These pendant groups can be easily 
chemically modified. This fact can be used to functionalize the dendrimer with targeting 
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ligands able to direct it to the desired tissue [47,50-52].  
Dendrimers fit with the definition of “nanocarrier’’, term used to describe “the hybrid 
multifunctional systems with sizes typically ranging between 1-200 nm which may 
deliver the bioactive agent at the targeted site with improved therapeutic activity over 
the free form of bioactive agent [53]”. Although the use of dendrimers in drug delivery 
is yet less developed than most of the previously described drug carrier systems, as it 
will be shown in this review, they present high potential for ocular drug delivery and 
have demonstrated to be useful in different ophthalmic administration routes. 
 
1.2. Biomaterials used in the preparation of nano and microsystems for ocular 
drug delivery 
1.2.1. Microparticles and nanoparticles 
Depending on the nature of the polymer (erodible or biodegradable and non erodible or 
non biodegradable) micro and nanoparticles can disappear or remain in the site of action 
after releasing the drug. Among the biodegradable polymers employed to prepare micro 
and/or nanoparticles the most used have been polyesters (lactide and glycolide 
copolymers, polycaprolactones, poly(β-hydroxybutyrates)), polyamides (including 
natural polymers such as collagen, gelatin, and albumin, or semisynthetic pseudo-
poly(amino acids) polymers such as poly(N-palmitoyl hydroxyproline ester)), 
polyurethanes, polyphosphazenes, polyorthoesters, polyanhydrides and poly(alkyl 
cyanoacrylates) [54,55]. In this review we will spotlight in some of the most relevant 
biomaterials. 
Some of the first attempts to administrate NPS on the ocular surface were carried out 
with poly(alkyl cyanoacrylate) (PACA) nanosystems in the 80’s [56]. PACAs are 
hydrophobic bioerodible polymers commonly used as tissue adhesive. They are 
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biocompatible polymers that degrades in vivo by hydrolysis of ester bonds of the alkyl 
side chain of the polymer, leading to water soluble degradation products, alkylalcohol 
and poly(cyanoacrylic) acid [57]. Currently, these polymers have been replaced in the 
development of particulate systems for ocular drug delivery. 
Chitosan (CSN) has been widely employed to prepare nanoparticles for ocular drug 
delivery. It is a cationic high molecular weight heteropolysaccharide composed mainly 
of β-(1,4)-2-deoxy-2-amino-D-glucopyranose units and partially of β-(1,4)-2-deoxy-2-
acetamido-D-glucopyranose. Free amino groups of chitosan can undergo protonation 
thus, making it soluble in aqueous acid solution (pH < 6.5), which avoids the use of 
hazardous organic solvents while handing it. Because of favorable biological properties 
such as biodegradability, biocompatibility and non-toxicity, chitosan has attracted great 
attention in pharmaceutical and biomedical fields [58,59]. Its cationic nature makes it an 
interesting candidate to DNA electrostatic complexation [60]. Furthermore, chitosan has 
bioadhesive nature, by electrostatic interactions with the negatively charged at 
physiologic pH of the mucins sialic acid groups [61,62]. This interaction with mucins 
has been used by several authors to improve the bioavailability of drugs after topical 
instillation by increasing the ocular surface retention time of drugs encapsulated in 
chitosan NPs. CSN can be used to prepare nanoparticles alone [63-66] or in 
combination with other compounds such as alginate [67], lecithin [68], etc. Some 
interesting combinations of chitosan with other polymers such as hyaluronic acid have 
demonstrated to be also useful in gene transfection at corneal level [69,70]. CSN is also 
an interesting biomaterial to coat NPs, liposomes or niosomes, improving their 
mucoadhesiveness on the ocular surface and the drug corneal permeation [41,64,71]. 
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The most widely employed polymer to prepare biodegradable nano and microspheres 
are the lactic and glycolic acid polymers and their derivatives: poly(lactic) (PLA), 
poly(glycolic) (PGA) and their copolymers poly(lactic-co-glycolic) acid (PLGA). These 
polymers are already approved for human purposes by the FDA and EMA. A 
biodegradable implant (0.45 x 6 mm) prepared with PLGA and loaded with 
dexamethasone (Ozurdex®) has been recently commercialized to treat persistent 
macular edema associated with diabetes, retinal vein occlusions, uveitis and post-
cataract surgery [72]. PLA, PGA and PLGA are well tolerated in vivo and accepted for 
parenteral administration. Their biodegradation products, lactic and glycolic acids, are 
also biocompatible and easily eliminated from the body thorough Kreb’s cycle [73]. The 
rate of degradation of PLGA systems depends on: (1) the copolymer molecular weight, 
length of lactic and glycolic blocks and ratio of lactic and glycolic acids  (2) structure 
and morphology, such as crystallinity and shape of the sample, (3) the way the materials 
are processed, (4) the particle size (total surface area) (5) the type and amount of drug 
contained in the formulation and (6) the environment in which the system is placed [74-
79]. Modifying these factors, the degradation rate can be varied from days to months. 
For example, 50:50 lactide/glycolide copolymers have an in vivo half-life of degradation 
of several weeks, whereas 65:35, 75:25 and 85:15 lactide/glycolide copolymers have 
progressively longer degradation half-life [55].  
Poly(-caprolactone) (PCL) is a material approved by the FDA for human use also 
widely used in the preparation of nano and microspheres. It is an aliphatic polyester able 
to undergo bulk erosion by random hydrolytic chain cleavage in physiological 
conditions in the human body. The degradation of PCLs may require from 2 to 4 years, 
which is especially interesting for the preparation of long term implantable devices. 
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However, the degradation process can be modulated with the use of additives able to 
enhance the hydrolytic reaction of degradation[55].  
In the case of SLNPs, the lipids employed are usually triglycerides, partial glycerides, 
fatty acids, steroids or waxes. All types of emulsifiers can be used but, depending on the 
lipid selected, the efficiency of the combination to prevent particle agglomeration has to 
be adapted.  
 
1.2.2 Liposomes 
Liposomal membranes are normally composed by a mixture of phospholipids of natural 
or synthetic origin. Among the natural phospholipids, those from egg or soybean 
lecithin (phosphatidylcholine (PC), phosphatidylserine, glycerosphosphocoline, etc ) are 
principally employed. Concerning the synthetic phospholipids, the most used are 
phosphatidylcholines derivatives (dipalmitoylphosphatidylcholine (DPPC), 1,2-
dimyristoyl- sn-glycero-3-phosphocholine (DMPC), etc.) [80], 
phosphatidylethanolamines (dimyristoylphosphatidylethanolamine (DMPE), etc) [81], 
phosphatydilserines (2-Dioleoyl-sn-glycero-3-phospho-L-serine (DOPS), etc), 
phosphatidic acids (2-Dipalmitoyl-sn-glycero-3-phosphatidic acid (DPPA), etc) and 
PEGylated phospholipids (1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-
[maleimide(polyethylene glycol)-2000] (MPEG-2000-DSPE), etc) [82]. To obtain 
positively-charged lipid vesicles cationic lipids as dioleoyl-3-trimethyleammonium 
propane chloride (DOTAP) or stearylamine (SA) can be included in the bilayer. To 
prepare negatively-charged liposomes anionic compounds as dicetylphosphate (DP) are 
employed [20]. 
Lipid vesicles also commonly include additives as cholesterol (Cht) and antioxidants as 
α-tocopherol or ascorbic acid. Cht improves the mechanical properties of bilayers, 
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provides rigidity to the liposomal membranes and avoids the lost of encapsulated drugs. 
Antioxidants, are also commonly incorporated to protect the phospholipid from 
oxidation [83,84]. These compounds avoid lipid peroxidation and can also have 
therapeutic effect. Furthermore, sphingosine, glycoplipids or other amphiphilic 
compounds such as polyethylene glycol (PEG) can be added to modify intrinsic 
properties of liposomes [85,86].  
 
1.2.3. Microemulsions and niosomes 
The amount and type of surfactants and co-surfactants, required to achieve the pseudo 
ternary-phase diagram corresponding to the ME region, are a critical point to elaborate 
MEs for ophthalmic administration, as ocular tolerance must be assured [87]. The most 
frequently used are non-ionic surfactants as poloxypropylene/polyoxyethylene block 
copolymers (poloxamers), polysorbates, polyethylene glycol and tyloxapol. 
Amphiphilic surfactants as lecithin are also often employed. Hwever, ionic surfactants 
are actually toxic to the ocular surface so their use in ocular formulations is very 
restricted. The co-surfactant provides higher fluidity of the interfacial film and a higher 
mean drop size which ensure a homogeneous repartition of ME compounds among 
droplets [88]. The most used co-surfactants are glycols, amines of short chains and low 
molecular weight alcohols (except hexanol and pentanol due to their high toxicity). 
The choice of the oily phase depends mainly on the drug solubility. Usually, polar oils 
and triglycerides with medium or long chains are preferred because of their ability to 
form micelles in the inner aqueous phase and solubilize lipophilic drugs. The oily phase 
selected has to be well tolerated in the eye. Vegetable oils (soja oil, castor oil) 
triglycerides, Miglyol 812® (caprylic/capric acid triglyceride), isopropyl myristate, fatty 
acids as oleic acid and esters of saccharose are the most used [32,89,90]. The aqueous 
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phase must contain additives as electrolytes, antibacterial compounds and isotonic 
agents. It has to be mentioned that these components of the aqueous phase can 
dramatically influence the ME formation and its stability, so extensive formulations 
studies are required [32].  
In case of niosomes, non-ionic surfactant (polysorbate, sorbitan esters, 
polyoxyethylenes, etc.) are used. Cholesterol is usually included in a 1:1 molar ratio 
(non-ionic surfactant: cholesterol) in most formulations to stabilize the bilayer [38]. 
Similarly to liposomes, several molecules can be also included in the formulation to 
obtain negatively and positively charged vesicles [40]. 
 
1.2.4. Dendrimers 
There are two general synthetic approaches used to generate dendrimers: (i) divergent, 
and (ii) convergent. The appropriate route depends mainly on the kind of monomer 
employed and the target polymer structure [43]. In the divergent approach the 
dendrimer is synthesised from the core as the starting point and built up layer by layer 
(generation by generation) [91]. The alternative convergent approach [92] starts from 
the surface and ends up at the core, where the dendrimer segments (dendrons) are 
coupled together [47]. Other synthetic strategies such as the “lego” or the “clic” 
chemistry are also being explored to obtain dendritic structures [48,93]. It is worthy to 
mention that the synthesis of dendrimers is not only limited to almost spherical 
structures, but also to the synthesis of hybrid systems, such as dendritic branched 
polymers, grafted-dendritic structures, cyclodextrin-dendrimers hybrids, etc. [94,95]. 
Although there is wide literature concerning the synthesis of dendrimers and their use in 
different fields (biosensors, catalysis, etc.) [96], only a few families of dendritic 
structures are currently being evaluated for their use in biomedicine, due to 
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biocompatibility issues [97]. The most promising dendrimers currently under study for 
medical purposes are the polyamidoamine dendrimers (PAMAM) and the dendrimers 
derived from polyethylenimine, also named PPI, among others [46,49,98,99].  
 
1.3. Methods of preparation of nano- and microsystems for ocular drug delivery. 
Although there are a wide variety of methods of preparation of nano- and microsystems 
for drug delivery, in this review we will only focus on the methods mostly used to 
prepare systems destined to ocular administration. 
1.3.1. Microparticles 
Many microencapsulation procedures are modifications of the following basic 
techniques: solvent extraction/evaporation, aggregation by pH adjustment or heat, 
coacervation (phase separation) and spray-drying [100].  
Among them, for example, spray-drying has been used to encapsulate poor aqueous 
soluble drugs as triamcinolone acetonide (TA) and ciprofloxacin to treat ocular diseases 
[101]. This technique is relatively simple, although it is not useful for highly 
temperature-sensitive drugs. Furthermore, the resultant microspheres are not always 
able to efficiently control the drug release due to its highly porous structure. 
Coacervation is another method classically employed to microencapsulate drugs. In this 
technique the use of organic solvents and coacervating agents are required. These 
compounds can remain in the microparticles once prepared, producing ocular toxicity. 
The use of supercritical gases as phase separating agents has been recently introduced to 
avoid potentially harmful residues in the microspheres [101]. 
The technique for microspheres formation destined to ocular delivery most reported is 
the solvent extraction/evaporation method (evaporation of a solvent from an emulsion). 
This technique requires a dissolution or dispersion of the active substance in a first 
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solvent containing the matrix-forming polymer (inner phase). After that, the 
emulsification of this polymer solution in a second continuous phase immiscible with 
the inner phase is performed. Then, the extraction of the dispersed phase solvent is 
carried out by evaporation at room conditions or under vacuum. Finally, the immature 
microspheres are harvested and freeze-dried or desiccated. Lyophilization is preferred 
because the stability of the final product is increased. Depending on the drug solubility, 
oil-in-water (O/W) or oil-in-oil (O/O) emulsions can be prepared. In case of 
polypeptides, proteins and other biotechnological products techniques based on the 
water-in-oil-in-water (W/O/W) emulsion, in which the active is first dissolved in the 
inner aqueous phase (W1), are generally chosen [102]. However, knowing the 
instability of such macromolecules in the organic-aqueous interfaces formed [103,104], 
some alternatives are currently under study to avoid such problem, such us the inclusion 
of albumin or PEG as stabilizers [105], or the use of the macromolecules in its solid 
state by the formation of a solid-in-oil-in-water emulsion (S/O/W) [106,107]. 
 
1.3.2. Nanoparticles 
There are several methods to prepare NPs that can be classified by whether (a) the 
formulation requires a polymerization reaction, (b) the formulation is achieved directly 
from a macromolecule or preformed polymer, (c) the system is formed by a desolvation 
and denaturation process of natural proteins or (d) NPs are formed by spray-drying [5]. 
Other methods include (e) NPs prepared by the emulsification/solvent evaporation 
method or (f) by nanoprecipitation.  
Depending on the type of carrier, the materials used and the intended application, some 
methods are chosen over others. For example, to prepare PACA NPs the preferred 
methods are the emulsion polymerization method and the interfacial polymerization 
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technique. In the first case nanospheres (size between 50 and 300 nm) stabilized with a 
stabilizing agent (poloxamer, dextran, etc.) are produced, while in the case of interfacial 
polymerization oil-containing nanocapsules are obtained [57]. 
Other methods applicable to a wide range of polymers are based in macromolecules 
denaturation (mainly natural proteins such as albumin or gelatin). The denaturation 
takes place typically by increment of temperature [108]. For termosensitive drugs, this 
denaturation can be produced through changes in pH, charge or addition of desolvating 
agents (such as ethanol or concentrated inorganic salt solutions) [109].  
An interesting method for NPs preparation using hydrophilic polymers such as chitosan 
is the ionotropic gelification. This technique is based on the cross-linking method using 
ionic counterions like tripolyphosphate, dextran sulphate, cyclodextrins or alginate as 
cross-linking agents [63,67,110], instead of toxic conventional cross-linking agents such 
as glutaraldehyde. This method has gained much attention because it is simple, non-
toxic and involves a mixture of aqueous phases at room temperature avoiding organic 
solvents [111]. In the case of chitosan NPs, they retain their cationic nature, required for 
its bioadhesiveness and permeating properties [112]. 
Other methods available to prepare NPs for ocular administration are the emulsion-
solvent evaporation method [113-115], spray-drying [116] (both previously described) 
and the nanoprecipitation method. To obtain particles in the nano-range using the 
emulsion method, the droplets formed during the emulsification step must be very 
small. To this, several methods as high shear homogenization, ultrasound or high 
pressure homogenization can be used [6]. In the nanoprecipitation method the polymer 
is dissolved in an organic solvent and then is added drop-wise to an aqueous phase that 
is stirred until the organic phase has been evaporated [117]. 
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1.3.3. Liposomes 
Some of the most widespread used procedures for liposomes elaboration are based on 
the thin-film hydration method (Bangham technique), sonication, extrusion, reverse 
phase evaporation (REV), freeze-thaw method, French pressure, ethanol injection or 
detergent dialysis [13,118-121]. When necessary, the preferred liposomal formulation 
can be elaborated by combining more than one strategy. 
The thin-film hydration technique consists on the solubilization of the lipid components 
in an organic solvent and its posterior slow removal by evaporation in a vacuum 
evaporator. A thin film of dry lipids is formed on the inner surface of the evaporator 
flask. Next, lipid film is hydrated with an aqueous solution and liposomes are formed 
spontaneously [13]. After that, and to obtain an homogeneous vesicles size, sonication 
and/or extrusion by polycarbonate membranes can be carried out. An schematic 
representation of this procedure is presented in figure 2.  
The freeze-thaw method is an extension of the lipid film hydration method. Once 
formed, liposomes are vortexed with an aqueous solution until the lipid film is 
completely suspended and MLV are frozen, vortexed again and extruded. In this process 
SUVs are ruptured and defused to form LUVs. During this procedure the solute is 
allowed to equilibrate between the aqueous core and outside the liposomes. As many 
freeze/thaw/extrusion cycles as necessary are performed. This method is widely used to 
protein entrapment [122]. 
Liposomes can be also performed by sonication of a lipid mass dispersed in the aqueous 
solution (large scale manufacture liposome) followed, if necessary, by extrusion 
processes [123]. 
The REV method is based on a co-solvated lipid solution that is dispersed in the 
aqueous solution with the drug. The lipid mixture is first dissolved in an organic solvent 
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that is evaporated under reduced pressure. After that, the formed lipid film is re-
dissolved in a different organic phase (diethyl-ether or isopropyl-ether), in which the 
lipid vesicles will be formed after the addition of the aqueous solution. The organic 
solvent is again removed under pressure to obtain a semisolid-gel. The resulting 
liposomes are called “REV liposomes”. LUV and oligollamelar vesicles are performed 
with this method directed to the encapsulation of large macromolecules [15]. 
 
1.3.5. Microemulsions 
ME are prepared by relatively simple, inexpensive processes that do not require of a 
complex technology. Basically, there are two main procedures for MEs preparation: (1) 
Autoemulsification process, where MEs are elaborated by spontaneous formation of the 
droplets when constituents are incorporated by gentle mixing and (2) process based on 
supply of energy by using a high-pressure homogenizer to obtain the droplet size 
desired after mixing the emulsion components.  
Niosomes intended for ophthalmic administration can be prepared using all methods 
already mentioned for liposomes, being the film hydration technique [38] and REV 
method [40] the most employed. 
 
1.3.6. Dendrimers 
The unique structure of dendrimers, with units branching from a core with void spaces 
within and between the branches, and an abundance of surface functional groups, makes 
them useful for complexing or entrapping various therapeutic agents. Hydrophobic 
drugs are typically located inside the structure, in the dendrimer core, through 
hydrophobic interaction, in a “host-guest” system [47,48,124,125]. In fact, PAMAM 
dendrimers can be used to increase the solubility of hydrophobic drugs such as 
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ibuprofen, 5-aminosalicylic acid or diclofenac [126-128]. Hydrophilic drugs are 
generally located on the dendrimer surface, thanks to electrostatic interactions 
(complex) [52,129,130] or covalent links (conjugates) [131-135]. In all cases drugs are 
continuously released from the systems for hours [127-131]. A specific case of dendritic 
complex is the combination of cationic dendrimers and oligonucleotides (OND). The 
complex is called dendriplexes [43,48,136], by analogy with similar complexes formed 
by liposomes and DNA called lipoplexes. The dendrimer-OND interaction is due to the 
characteristic high density of positive charged on the dendrimer surface 
[48,99,136,137]. Dendriplexes are able to protect the nucleic acid from degradation and 
enhance the transfection in comparison to naked OND. They are considered one of the 
most promising non-viral vectors currently in development for gene therapy 
[93,125,136,138].  
 
1.4. Routes of administration of nano and microsystems for ocular drug delivery  
As mentioned before, the location of the target tissue in the eye will determine the route 
of drug administration. As the eye is designed to avoid the entrance of exogenous 
substances, the drug must overcome the different protecting barriers to achieve the 
target tissue. In this section we will briefly describe the characteristics of each 
administration route underlining the main advantages and disadvantages. The different 
administration routes described in the text have been compiled in figure 3. 
 
1.4.1. Topical administration 
As previously commented, although the ocular topical administration of drugs offers 
obvious advantages such as easily administration and no need of qualified healthy staff, 
it undergoes important limitations. The main drawback is the low bioavailability of 
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drugs due to rapid clearance from the ocular surface and limited permeability through 
the cornea. Furthermore, topically administered drugs cannot reach the back of the eye 
in effective concentrations so its utility is restricted to the treatment of diseases affecting 
the ocular surface and when the drug has to reach the anterior segment of the eye.  
The technological strategies used to increase the bioavailability of active substances 
after ocular instillation are based on the increment of their retention time on the ocular 
surface, mainly by interaction with ocular mucins, and on the corneal permeability 
enhancement. In that scenario, the use of solid microsystems is quite limited, due to 
their size. On the contrary, mucoadhesive nanosystems (nanoparticles, liposomes, 
niosomes, dendrimers, etc.), able to attach to the ocular surface and microemulsions 
offer, as it will be presented in this review, a very promising approach. 
 
1.4.2. Intraocular administration 
Intraocular administration involves the deliver of a relatively high dose of drug inside 
the eye with few or no systemic side effects. It includes several administration routes 
covering the anterior (intracameral administration) and the posterior segment 
(intravitreal administration, subretinal administration, etc.). 
Although “intracameral” can be literarily used to define “injection of drug in the ocular 
globe”, it is exclusively used to describe the injection of formulations into the anterior 
chamber of the eye. This route is generally used during cataract surgery.  
The intravitreal injection of drugs is the most efficient route to treat disorders in the 
back of the eye. This administration route presents clear advantages in comparison to 
topical and systemic administration. Furthermore, this local administration assures a 
very low prevalence of systemic side effects. However it is accompanied of important 
disadvantages. The first one is that it is an invasive route so the injection is performed 
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directly in the ocular cavity. This provokes rupture of delicate tissue structures and also 
compromises the immunity privilege of the eye, which can cause infections. 
Furthermore, as direct deposit of the drug is performed, retinal toxicity can be produced 
due to the initial high concentrations achieved. Secondly, for most of the active 
substances, the clearance from the vitreous is very rapid, with elimination half-lives of 
few hours in most of the cases. This involves the need of frequent repeated injections, 
which in turns, increases the risks associated to intravitreal injection, such as 
endophthalmitis, damage to lens or retinal detachment among others. 
Chronic ocular disorders can be most efficiently treated by maintaining the drug 
concentrations within the therapeutic window at the target tissue in the eye and reducing 
the frequency of administrations. To reach this goal microsystems are useful tools 
currently under development. As it has been already mentioned, the main advantage of 
these systems is that they can control the release of the active substance for weeks, even 
months, reducing the frequency of injections and maintaining sustained adequate 
concentrations in the vitreous. In the case of nanosystems, their utility is more focused 
on the protection of the active substances of the external environment and their targeting 
to damaged ocular tissues. This strategy is of especial relevance in the case of active 
bioengineered compounds (peptides, proteins, nucleic acid etc.). 
Alterations in the outer retina can be also treated by subretinal injections. The risk of 
this administration is evident and it is currently tested in preclinical studies. Cai et al, 
for example, have evaluated the subretinal administration of DNA-peptide NPs to treat 
the photoreceptors degeneration [139] 
 
1.4.3. Periocular administration 
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Periocular injections are a less invasive alternative, potentially safer than intraocular 
injections, that offers an interesting approach for retinal drug delivery. Periocular refers 
to the region surrounding the eye and is a general term that includes peribulbar, 
posterior juxtascleral, retrobulbar, sub-tenon and subconjunctival routes. Depending on 
the injection, a drug administered by this route can access the target sites in the 
posterior segment through the sclera, the choroid and/or aqueous humor and vitreous. 
Drugs can reach intraocular tissues after periocular administration, even if they are 
macromolecules or low-molecular-weight drugs. However, they can be rapidly 
eliminated from the administration site, via the lymphatic flow in the conjunctiva and 
episclera, and/or the blood flow of the conjunctiva and choroid.  
Although the periocular administration of drugs has been used primarily to be targeted 
to the anterior segment (anti-inflammatory agents and anesthetics by subconjunctival 
injection) [140], the interest of this route is now also directed to the posterior segment 
and, specifically, to retinal delivery as an alternative to intravitreal injections [141-143]. 
While intravitreal injections have shown to be more effective to treat retinal ganglion 
cells and inner retinal interneurons disorders, it has been demonstrated that periocular 
injections are more effective for delivery to the outer retina (photoreceptors and RPE) 
[144]. 
 
1.5. Specific requirements for ocular drug delivery 
1.5.1. Sterility 
A mayor concern in the administration of ophthalmic formulations is to avoid microbial 
contamination. For this reason, a properly sterilization and maintenance of the systems 
is always required prior to and/or during their use. A final sterilization is preferred over 
the preparation of the formulations under aseptic conditions. Among the available 
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sterilization methods, sterilization by membrane filtration, ethylene oxide, gamma 
irradiation and autoclaving are included.  
A number of drawbacks limit the utility of these methods in ophthalmic drug delivery. 
These limitations are usually related to the stability of the materials (drug and/or 
polymer) or the production of toxic residues during the process. Some of the 
biomaterials commonly used to prepare micro and nanosystems for ophthalmic 
administration, such as PLGA or phospholipids, are sensitive to the conventional 
sterilization methods usually employed (heat and ethylene chloride).  
In the case of polymers, gamma irradiation is the preferred option. It has a high capacity 
for penetration (the dose required to assure sterilization of a pharmaceutical product is 
25 kGy) [145]. However, gamma-irradiation of bioresorbable polyesters, such as PLA 
or PLGA, induces dose-dependent chain scission as well as molecular weight reduction, 
affecting the properties of the final product [146]. The degradation rate of polymeric 
biomaterials due to gamma-irradiation has been linked to radical formation [147]. This 
problem seems to be diminished by using low temperatures during the exposure time of 
the different systems to gamma-radiation and has been already reported for sterilization 
of microspheres [145]. In the case of PLGA microparticles, several studies have 
demonstrated that gamma irradiation under low temperature did not change the essential 
characteristics of formulations; drug release rate, morphology, particle size and particle 
size distribution, etc. [148,149].  
Nanoparticulate systems could also be potentially sterilized by other methods such as 
sterilization by membrane filtration, or autoclaving. Sterilization by filtration does not 
affect materials’ properties (polymer or drug) since it is based on physical removal of 
microorganisms through 0.22 µm membrane filters. However, it can only be used with 
NPs which have a narrow size distribution and a mean particle size below 200 nm to 
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avoid membrane clogging, and it is not suitable when the drug is adsorbed at the NPs 
surface or when the suspensions are too viscous. Heat sterilization by autoclaving is a 
highly effective technique but involves high temperatures (120ºC) that may produce 
degradation or decomposition of the material (polymer and/or drug). Although this 
technique is not suitable with most systems, solid lipid NPs can be sterilized by 
autoclaving. It has been shown that after autoclaving, SLNPs almost maintain the 
spherical shape without any significant increase in the size of the NP distribution [7].  
Concerning liposomes, sterilization presents serious difficulties that compromise the use 
of liposomes as drug delivery systems. Sterilization by heating can degrade liposomes 
as they are thermolabile and lipids can be hydrolyzed with high temperatures 
(autoclaving at 121ºC or by gamma irradiation). Therefore, the most indicated 
sterilization method is based on filtration by polycarbonate membranes of 0.22 µm pore 
size, nevertheless if liposomes of 0.22 µm diameter of less are not the desired end point 
this filtration step cannot be used to sterilize the liposomes products. In addition, phase 
transition temperature determines filtration process, and liposomes passing through 0.22 
µm can modify their size. Hence, in these cases, working under aseptic conditions from 
the beginning of the elaboration process combined with sterilizing filtration (if possible) 
is the selected alternative [85]. 
So, the deficient and chemical stability of lipid vesicles and the loss of stability during 
heating limit the sterilization methods to sterile filtration and aseptic working 
conditions. Nevertheless, lyophilisation is one of the most promising methods to keep 
liposomes stable during long term storage[150]. As we previously commented, 
liposomes are susceptible to chemical and physical instabilities as fusion/aggregation of 
lipid membranes, precipitation phenomena, drug loss, lipid oxidation, phospholipid 
hydrolysis, etc. Lyophilisation or freeze-drying technique offers the opportunity to 
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remove water from liposomal systems resulting in a solid porous cake which must be 
reconstituted with aqueous solutions before use. After freeze-drying, the porous cake 
can be sterilized by gamma irradiation without serious damage for the liposomal system 
preventing hydroxyl radicals formation by water exposition to gamma irradiation. 
Hence, freeze-drying enhance liposomal stability and protects lipid vesicles from 
alterations during gamma irradiation process.  
As usual, lyophilisation technique requires a good defined protocol [151-153] and in 
addition, presents some disadvantages: Lipid bilayer of phospholipids can result 
damaged by crystal formation during freezing process and, water removal during 
sublimation step can lead to a disruption of the lipid bilayer. As consequence, 
aggregation/fusion phenomena can occur during the hydration step and liposomal 
system is modified. Nevertheless, there are strategies directed to protect liposomes from 
water removal alterations. Composition of lipid bilayer is one of the factors to take into 
account, the addition of cholesterol and vitamin E avoids crystal formation during water 
removal. Nowadays, cryoprotectors are frequently used with good results to overcome 
problems derived from freeze-drying. Saccahrides as sucrose, lactose, dextran, trehalose 
and other molecules as lysine protect phospholipids from water removal modifications 
since sugars can replace the water molecules as sublimation occurs and thereby bilayer 
conformation remains stable. A vitrification model has also been proposed for 
saccahrides, especially for trehalose, which also protects phospholipid during freeze-
drying process by a vitreous layer formation around the lipid membrane[154]. The ratio 
sugar/phospholipids should be appropriate for freeze-drying protocols in order to 
protect liposomes from lyophilisation process maintaining physical and chemical 
properties and stability after rehydration of the anhydrous cake[152]. In some cases, 
polymers as hyaluronic acid can act as cryoprotectants, so the use of bioadhesive 
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polymers is an important technological resource for formulations destined to ophthalmic 
route[155]. As an example, Ahmad et al. developed mitoxantrone liposomes (DOPC, 
cholesterol, cardiolipin, alphatocopheryl succinate) by ethanol injection technique. As 
lyoprotectant, sucrose or trehalose was employed at different concentrations. There 
were no differences in size pre-lyo and post-lyophilisation formulas when sucrose/lipid 
ratio 7.5/1 was used. The lyophilized formula resulted stable for 13 months after storage 
at 2-8ºC and liposomes reconstituted were physically and chemically stable for 8 hours 
at room temperature (20–25ºC)[156]. 
After lyophilisation of liposomes, sterilization by gamma irradiation can be performed 
at a dose of 25 KGy following European Pharmacopea guidelines[157]. Physical and 
chemical studies before and after lyophilisation and sterilization processes are required 
to check if alterations in the liposomal systems appear. Perrie et al. developed a 
combined technique based on freeze-drying and posterior gamma sterilization applied to 
liposomal vaccines containing a protein able to responses against Mycobacterium 
tuberculosis. Cationic liposomes, composed by dimethyldioctadecylammonium 
bromide, 1.25 mg/ml; and α,α’-trehalose 6,6-dibehenate, 250 µg/ml, carried out by 
solvent evaporation method. Cryoprotectants as sucrose, trehalose and lysine were 
tested to obtain the optimal ratio for stability and sterility posterior studies. The freeze-
drying protocol consisted of pre-freezing liposomal formulation at -70ºC for 30 minutes 
and followed by drying in two steps: -50ºC for 48h and at -30ºC to 20ºC for 6 h. After 
that, gamma sterilization at a dose of 25 KGy (room temperature) was carried out. 
Lysine, sucrose and trehalose /liposomal formula in a ratio 4/1, 8/1 and 10/1 
respectively were the most effective concentrations to show lyoprotectant effects. Mean 
volume diameter size, zeta potential, dynamic viscosity, pH and residual moisture 
content, among others, were measured prior to and post sterilization. Results show no 
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differences for each parameter analyzed after gamma irradiation, except pH which 
values were not influenced by sterilization but for cryoprotectant choice [158]. 
As conclusion, lyophilisation and posterior gamma irradiation can result appropriate 
methods to enhance stability and sterility of liposomal formulations, nevertheless, 
cryoprotectants choice, freeze-drying protocols and gamma irradiation doses have to be 
evaluated carefully.  
 
Microemulsions sterilization processes are relatively simple and easy to carry out.  
Sterilization by autoclaving or sterilizing filtration are good alternatives for these 
systems [159]. No extended studies about niosomes sterilization are available, however, 
the mentioned sterilization for ME, except filtration, that similarly to liposomes, could 
modify the vesicles size, might be also applied for niosomes. In the case of dendrimers, 
thanks to their small particle size (tipically lower than 10 nm) they should be sterilized 
by sterilizing filtration through 0.22 µm membrane. However, to our best knowledge, 
no extensive studies have been performed in this sense. 
 
1.5.2. Tolerance 
Tolerance studies for ophthalmic formulations can be performed in-vitro and in vivo. In-
vitro tolerance involves viability assays in cell lines. There are different cell lines to 
perform these studies. Immortalized corneal and conjunctival cell lines are employed to 
evaluate tolerance of topical formulations[160-165]. Immortalized ARPE cell lines and 
primary cultures of retinal cells[166-169] are employed for formulations destined to 
intravitreal administration. Other immortalized cell lines as macrophages are useful to 
test in vitro tolerance as they are very sensitive. 
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In vivo ocular tolerance of drug delivery systems depends on their composition and site 
of administration. 
In vivo tolerance of topical formulations has been examined by several authors. For 
example, Contreras-Ruiz et al. evaluated the alterations of the tear film physiology and 
ocular surface tissues after the instillation of hyaluronic acid-chitosan NPs in rabbit 
eyes[170]. 30 µl of a NPs suspension (0.5 mg NPs/ml of buffer) were instilled every 30 
minutes for a period of 6 hours. Clinical signs observed 24 hours later were compared 
with those obtained just before the instillation. No signs of ocular discomfort or 
irritation after exposure were shown and ocular surface tissues and tear film physiology 
remained unchanged. Nagarwal et al. evaluated the tolerance of 5-fluorouracil loaded 
chitosan NPs applied topically in rabbit eyes. In this work authors used the Draize test 
to check swelling and discharge of the conjunctiva and corneal integrity. No signs of 
ocular inflammation, tissue alteration, conjunctiva congestion, swelling or discharge 
were reported[171].  
Liposomes are supposed to result no toxic for the ocular surface as the tear film contains 
a similar composition (aqueous phase and lipids components), however, cationic and 
anionic liposomes may induce some ocular toxicity produced by the surface charge 
[111,172]. Stearylamine is known to destabilize lysosome membranes and subsequent 
hydrolases release results in cellular damage. SA-liposomes also produce ocular surface 
toxicity as function of SA concentration [173,174]. Taking these studies into account, 
Schaeffer et al. demonstrated the adequate tolerance of a indoxole liposomal 
formulation composed by PC:SA:Cht in a molar ratio 7:2:1. Authors administered the 
liposomes preparation in male Sprague-Dawley white rats twice daily for 8 days and 
evaluated changes of corneal cells. The histological evaluation of rat corneas did not 
show ocular toxicity as stroma hyalinization [175].  
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Alonso et al. designed a system combining liposomes and chitosan nanoparticles to 
apply as eye drops. Liposomes were prepared according to the solvent evaporation 
method followed by extrusion at phase transition temperature until desired liposome 
size close to 400 nm was obtained. Three different liposomes compositions were 
prepared: L1 consisted of di stearoyl phosphatidylcholine:di palmitoyl 
phosphatidylserine:cholesterol (DSPC :DPPS:Cht (6:0.1:3 molar ratio), L2 consisted of 
DPPC:Cht (6:4 molar ratio) and L3 was composed of DSPC:Cht (6:4 molar ratio). After 
that, the liposomes-chitosan nanoparticles were performed by freeze-drying process. 
The size of the complexes ranged from 750 to 400 nm and the surface zeta potential was 
between +6 and +15 mV. These complexes resulted well tolerated by the ocular surface 
as they did not present toxicity when incubates with IOBA-NHC cells. Besides, in vivo 
studies on New Zealand rabbits demonstrated that these nanosystems were non-
irritating and compatible with ocular surface [71]. 
Concerning ME, Benita et al., for example, developed a positively-charged emulsion 
with phospholipids, poloxamer 188 and SA which employed in an acute ocular 
tolerance assay in rabbit eyes. Administration of a drop hourly of the cationic 
microemulsion was well tolerated with no damage on the ocular surface during the 5 
days of the study [176]. However the toxicity of surfactants and co-surfactants may 
compromise ocular tolerance so deep studies are necessary for each individual ME 
formulation [89]. 
The scarcely number of niosome tolerance studies performed, in vitro and in vivo, 
showed no signs of toxicity. Abdelbary and El-gendy (2008) prepared niosomes using 
three different non-ionic surfactants: polysorbate 60 or polysorbate 80 or 
polyoxyethylene lauryl ether, always in combination with Cht and PD. Authors tested 
the presence of any redness, inflammation or increased tear production upon the 
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application of each niosomal preparation to the eye of albino rabbits. Observations were 
performed at 1, 24 and 48 hours after instillation using the contralateral eye as control. 
No signs of toxicity of damaged tissues were observed [38]. More recently, Abdelkader 
and collaborators (2012) performed a complete study conjunctival and corneal toxicity 
of niosomes combining different in vitro tests: The hen’s egg test-chorioallantoic 
membrane (HET-CAM), bovine corneal opacity and permeability (BCOP) test and 
histological examination of excised corneas [177]. They tested niosomes prepared with 
and loaded with Cht, DP, Sorbitan monostearate (Span 60), poly-24-oxyethylene 
cholesteryl ether (C24) sodium cholate (CH) and also tested each isolated components. 
Only one of the tested ingredients, CH, showed moderate irritation, however such an 
effect was diminished when incorporated into niosomes. 
It is generally accepted that the cationic dendrimers are less tolerated than the anionic 
ones. Authors referred this lower tolerance to the high density of positive groups on the 
dendrimer surface that can disrupt and alter in some extent the biological membranes 
[178,179]. However, some authors have administered PAMAM dendrimers on the 
ocular surface showing a similar toxicity behavior than linear polymers. Vandamme and 
Brobeck [180] tested the tolerance of 2% of PAMAM (4G) solution with different 
chemical groups on the surface (amino, carboxyl and hydroxyl) groups on albino 
rabbits. The clinical observations and ocular reactions (redness, conjunctival chemosis, 
discharge, iris and corneal lesions), evaluated 1, 24, 48, 72, 96 h and 7 days after 
application, revealed that the aqueous polymer solutions of the dendrimers tested did 
not cause any ocular irritation and did not induce a watering reflex. However, Lopez 
and co-workers (2009) observed that cationic PAMAM (G3 & G5) dendrimers resulted 
relatively toxic for the corneal epithelium at concentrations 1.3-12.5 g/ml. These 
authors demonstrated that the coupling of the dendrimers with PEG chains importantly 
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reduced the toxicity of the systems [181].  
PLA and PLGA are the most studied polymers for intraocular administration. Regarding 
micro and nanoparticles prepared with PLA and PLGA, they have been mainly 
administered by intravitreal and periocular route. In the tolerance studies performed in 
animal models (rabbits) and humans it has been observed that once injected in the 
vitreous, PLGA microparticles suffer aggregation [3,182]. Preliminary investigation in 
25 human eyes showed that this tendency of the PLGA microspheres to aggregate and 
condensate at the site of the injection have a positive effect, not only because they act as 
in situ implant, diminishing the surface area and probably prolonging the drug release 
time, but also because this aggregation leaves free visual axis, so patient’s vision is not 
compromised [3]. Once in the vitreous PLA and PLGA begin to hydrolyze, 
disappearing in several weeks [3,182]. In studies carried out by Moritera et al., the 
elimination of these polymers from the vitreous seems to accelerate in eyes underwent 
vitrectomy in rabbits [183]. Although no histologically retinal nor choroidal damage 
were reported after intravitreal injection of PLGA microspheres by Koobehi and co-
workers [184], a mild localized foreign body reaction was denoted by Veloso et al., 
[185], similar to the ones reported for sutures and disappeared 2-4 weeks after 
administration [182]. Authors observed that this foreign body reaction, associated with 
PLGA in the eye gradually decreased with time, was similar to that described for 
microspheres intramuscularly injected in rabbits [186]. In the case of PLGA NPs, Gupta 
et al analyzed the ocular tolerability of sparfloxacin loaded PLGA NPs with the hen’s 
egg chorioallantoic membrane test (HET-CAM) [187]. For the procedure, 0.5 ml of the 
formulation were instilled directly onto a 2x2 cm window made in the shell, allowing 
the formulation to be in contact with the chorioallantoic membrane for 5 minutes. Then, 
vascular damage was assessed. Results indicated that sparfloxacin NPs were nonirritant 
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and well tolerated. Zang et al administered 100 µl of a dexamethasone (Dx) loaded 
PLGA NPs suspension (equivalent to 2 mg of Dx) with a 30G needle into the vitreous 
cavity in rabbit eyes [188]. NPs allowed a sustained release of Dx for at least 50 days in 
the tissues and, after a certain time, they gradually sedimented to the areas next to the 
retina. Clinical observation, including fundus observation and photography, IOP 
measurement and B-scan ocular ultrasonography were used to determine possible 
abnormalities that could be attributed to the intravitreal sustained-release of Dx from 
NPs, but authors did not find any evidence of this relation. 
Barbosa-Alfaro et al., have recently evaluated the tolerance of PLGA microparticles 
after sub-tenon injection. Five mg of dexamethasone (Dx) microspheres (165.6±3.6 
µgDx/mgMP) (828 µg Dx) were administered by sub-tenon injection in rabbits’ eyes. 
Neither adverse clinical nor histological signs were observed six weeks after periocular 
administration [189]. Only a moderated conjunctival congestion was observed in both 
eyes (treated and untreated) probably due to the sub-tenon injection itself [190]. Other 
authors either found any inflammation sing, including redness and edema after a single 
subconjuntival injection of 5 mg PLGA-microspheres loaded with celecoxib in rats 
[149].  
Considering intraocular particles prepared with other biopolymers, Merodio et al 
evaluated the retinal toxic response induced by ganciclovir (GCV) loaded bovine serum 
albumin NPs in Wistar rats’ eyes. 5 µl of a NPs suspension (200 mg NPs/ml equivalent 
to 5 mg GCV/ml), were administered with an intravitreal injection using a 29G needle. 
The effects of NPs administration were analyzed 1 week and 2 weeks post-injections. 
Albumin NPs in contact with the vitreous did not show evidence of inflammatory 
reaction in the retinal tissue, alterations of the surrounding ocular tissues or any 
autoimmune response able to stimulate photoreceptor degeneration[191]. 
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In vivo tolerance of intravitreous poly-Ɛ-caprolactone implants have been already 
performed in pigmented rabbits. In this study a device loaded with dexamethasone was 
inserted into the vitreous of the animals. Clinical and histologic observation 
demonstrated that the system resulted well tolerated in the animals[192]. 
The nature of the biopolymer is critical in terms of intraocular response. Rincon et al 
studied the tolerance of microparticles prepared from an elastin-like-family biopolymer  
(poly (valine-proline-alanine-valine-guanine; VPAVG). The thermoresponsive polymer 
did not induce any cytotoxicity on macrophages up to 60mg/mL. No inflammatory 
response was observed after subcutaneous injection in the hind-paw of rats. However, 
45% of retinal detachment was observed in the animals receiving intraocular injection 
of poly (VPAVG) microparticles (2,5mg)[15,193]. 
Periocular and intraocular liposomes administration also require tolerance studies 
Especially intravitreal injection can induce blurring vision, decrease of visual acuity and 
can lead to the apparition of opacities and cloudiness limiting their use for intravitreal 
purpose [194,195] [196]. Tremblay and co-workers intravitreally injected in 40 eyes of 
twenty pigmented rabbits amphotericine B (AmpB)-liposomal formulation (lipid 
composition PC:Cht:tocopherol succinate in a molar ratio 5:3:1 and AmpB 
concentrations of 1, 5, 10 or 20 ng). Control preparations, also injected, consisted on 
empty liposomes, PBS and free AmpB free. A part from the presence of vitreous bodies 
in most of the eyes injected, authors did not detect retinal damage in the group treated 
with Amp-Liposomes or empty liposomes. However, animal group received AmpB 
solution presented retinal necrosis or atrophy in 5 of the 16 eyes treated due to the 
intrinsic toxicity of the drug[197]. Freeman et al. developed a liposomal formulation 
composed by dioleyl phosphatidyl choline (DOPC), dimyristoyl glycerol (DMG), 
triolein and Cht entrapping a GCV derivative. Liposomes tolerance was studied after 
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intravitreal injection of drug loaded and unloaded liposomes showing no retinal damage 
for any of the preparation tested [198]. 
 
Hereafter the review will be focused on the description of research works published in 
the last decades that describe the high potential of microparticles, nanoparticles, 
liposomes, microemulsions, niosomes and dendrimers for ocular drug delivery. Some 
relevant studies in the field of gene therapy and transfection have been also commented 
in the corresponding sections. As summary and guidance for readers, the basic 
information of each study has been assembled in Table 2.  
 
2. MICROPARTICLES FOR OPHTHALMIC ADMINISTRATION 
Several preclinical studies have demonstrated the efficacy of microparticles releasing 
encapsulated molecules in a controlled manner from weeks to months depending on the 
polymer characteristics. These systems can be administrated by different ophthalmic 
routes (topic, intraocular and periocular) depending on the target tissue to which they 
are intended.  
 
2.1. Microparticles for topical administration 
The utility of microparticles for topical therapies of ocular diseases are limited by (a) 
the short residence time of the microparticles in the ocular surface and (b) the particles 
size, that should not exceed 10 µm to avoid scratching feeling [199,200]. For the above 
reasons the topical administration of microparticles is not very common, and only some 
authors have explored the possibility of using polymeric biodegradable microparticles 
to administrate drugs on the ocular surface. 
Recently, Addo et al. developed a topic microparticulate formulation of tetracaine that 
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produced an anesthetic action during common surgical procedures on the ocular. 
Microparticles (mean particle size of ~4 µm) were prepared by spray-drying method 
using a bovine serum albumin–chitosan (BSA-CSN) solution. This formulation 
presented a minimum cytotoxicity and optimum human corneal epithelial cells (HCET-
1) cellular uptake (detectable 15 min after instillation and maintained for at least 24 
hours). In vivo studies in rabbits showed that two drops of tetracaine microparticles 
(0.5%) suspended in saline solution increased the duration of anesthetic action of the 
drug up to 4-fold in comparison with the standard marketed solution while maintained 
the onset of action statistically similar to a commercial 0.5% tetracaine hydrochloride 
ophthalmic solution (Alcon Pharmaceuticals) [201]. 
As previously mentioned, one of the main reasons hindering the use of topical 
microspheres is its short contact time on the ocular surface. Some authors have 
developed bioadhesive microspheres to increase the drug bioavailability by prolonging 
the contact time of the formulation with the ocular surface. In this sense Sensoy and co-
workers studied the efficacy of topic treatment with bioadhesive microspheres loaded 
with sulfacetamide sodium (SLA) for the treatment of keratitis in rabbits. Microspheres 
were prepared by spray-drying method using natural (pectin), semi-synthetic 
(hydroxypropyl methyl cellulose -HPMC-) and synthetic (polycarbophil) mucoadhesive 
polymers combined at different ratios. Authors found that SLA-loaded polycarbophil 
microspheres (size 1.87µm) formulation had the highest production yield (62.7%), 
exhibited the lowest initial burst release within the first 5 min (15.25%) and prolonged 
the release rate of SLA (71% of the drug was released after 9 h), resulting the most 
suitable for ocular application. The in vivo studies carried out in rabbit eyes with 
keratitis showed that the eyes treated with polycarbophil microspheres suspended in 
light mineral oil completely eradicated the bacteria from eyes after 6 days of 
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administration twice a day of the microparticles formulation [200].  
Choy et al., [202,203] used PEG as a mucoadhesion promoter. These authors 
administered nile red-labeled PLGA-PEG microparticles (diameter lower than 10 μm) 
on the ocular surface of rabbits by instillation of the microparticles suspensions, or by 
the administration of mannitol minitablets containing the microparticles, in the cul-de-
sac. Authors observed that while the aqueous suspension induces tear production rapid 
and drainage, the minitables formed a microenvironment of relatively high viscosity due 
to mannitol dissolution increasing the microparticles retention time on the ocular 
surface up to 1 hour, according to fluorescence images. 
 
2.2. Microparticles for intraocular administration 
Intravitreal microparticles allow the release of the encapsulated drug bypassing the 
blood–ocular barrier. The main advantage of microparticles is that they can be injected 
as a suspension using conventional needles. The microspheres are suspended in a 
physiological vehicle, typically phosphate buffer solution (PBS) or balanced salt 
solution (BSS). In some cases more viscous vehicles; such as hyaluronic acid (HA) or 
HPMC solutions to improve the suspension’s injectability [185]. 
The use of microparticles as drug carriers to treat posterior segment diseases by 
intravitreal injection has been of great interest in the last decades. Many authors have 
tested this strategy to treat diseases such as proliferative vitreoretinopathy (PVR), age-
related macular degeneration (ARMD), diabetic retinopathy (DR), uveitis, macular 
edema or citomegalovirus (CMV) retinitis and most recently optic nerve diseases such 
as glaucoma and retinitis pigmentosa. 
Moritera and co-workers [183,204] prepared PLA microspheres loaded with 
adryamicin. Suspensions of microspheres (mean particles size 50 μm) were injected in 
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the vitreous of normal rabbit eyes and in a rabbit model of PVR. Authors observed that 
the retinal detachment was decreased from 50% to 10% in PVR rabbits after 4 weeks of 
the administration of 10 μg of the encapsulated drug. Authors found a significant 
decrease in the retinal toxicity of the single injection in comparison with the 
administration of the same amount of drug in solution, with no histological 
abnormalities, nor electrophysiological changes in the eye. Another interesting work 
was the study carried out by Giordano and co-workers [205] for the intravitreous 
administration of retinoic acid (RA) loaded in PLGA microparticles, also for the 
treatment of PVR in a rabbit model. The microparticles prepared in vitro released the 
drug for 40 days. In vivo studies showed that the incidence of tractional retinal 
detachment (TRD) resulted effectively reduced two months after a single injection of 
RA-loaded microspheres (110 μg RA) in comparison to blank microspheres. 
The intravitreal administration of antivirals drugs as acyclovir (ACV) and ganciclovir 
(GCV) using microparticles has attracted the attention of several research groups. For 
example, Conte et al. [206] developed a controlled release formulation from different 
PLA and PLGA polymers loaded with ACV using the spray-drying technique. The 
formulations were tested as an alternative to intravenous or intravitreous administration 
of the drug in solution in the treatment of acute retinal necrosis caused by virus 
injections. After in vivo injection of PLA microparticles (25 µm diameter) into rabbit 
eyes, drug levels were detected in the vitreous for fourteen days after administration. In 
an interesting study carried out by Veloso et al. [185] was tested the antiviral effect of 
GCV released from PLGA. GCV-loaded microspheres (size 300-500 µm) containing 
864.04 µg of the drug prepared from PLGA 50:50, were injected in infected rabbits’ 
eyes. In treated eyes, vitritis, retinitis and optic neuritis decreased during the 14 days of 
the study, in contrast to control eyes. Immunofluorescence of virus antigens in retinal 
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tissues was not shown in treated eyes. Histopathology analysis showed minimal focal 
disruption of the retinal architecture in eyes injected with GCV-loaded microspheres, 
while some was observed in eyes injected with blank microspheres. No adverse tissue 
reaction was clinically or histopathologically observed in the eyes injected with 
ganciclovir-loaded microspheres after 8 weeks. Authors concluded that these 
formulations should be an alternative to the frequent injections of GCV solution 
required to maintain intraocular therapeutic drug levels. In another study of 
microparticles loaded with GCV, Duvvuri and co-workers injected PLGA microspheres 
loaded with GCV dispersed in a thermogelling PLGA-PEG-PLGA solution in rabbits’ 
eyes. In this work, microspheres were prepared by the solvent evaporation method using 
PLGA polymers with different lactic:glycolic ratios (50:50 and 65:35). After intravitreal 
injection of microparticle formulation (196 µg of GCV), authors showed that drug 
levels in the vitreous were higher and maintained for prolonged time after the GCV-
microparticles injection (approximately 0.8 µg/ml for 14 days) in comparison with drug 
solution (above 0.8 µg/ml for 54 hours) [207]. 
Intravitreal administration of microparticles in the treatment of pathologies as 
intraocular immune disorders, uveitis and other intraocular inflammation has also been 
extensively investigated. PLGA 75:25 microparticles of approximately 50 μm loaded 
with Cyclosporine (CyS) were tested for the treatment of uveitis and other intraocular 
immune disorders. The particles maintained therapeutic concentrations for at least 65 
days in the disease-related tissues such as the choroid-retina and iris-cilliary body after 
injection into the vitreous body of healthy rabbits. The mean residence time of the 
active substance was increased around 10 times compared to CyS solution [208]. Barcia 
et al. [209] developed microspheres (53μm) for the sustained delivery of dexamethasone 
destined to prevent intraocular inflammation. Microspheres were prepared using PLGA 
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50:50 containing 1410 μg of dexamethasone and were injected in an animal model of 
uveitis provoked by lipopolysaccharide (LPS) injection. Authors showed that the 
intraocular inflammation was significantly reduced in animals receiving the Dx-loaded 
microspheres compared to control (blank microspheres). In order to simulate secondary 
uveitis a second injection of LPS was performed 30 days after microparticles 
administration. No inflammation was observed in the animals treated with 
dexamethasone loaded PLGA microspheres after this second LPS injection. 
It is interesting to remark that some studies performed with microspheres loaded with 
anti-inflammatory drugs have been already performed in humans. For example, Cardillo 
and co-workers [3] reported human studies of the intravitreal injection of TA-loaded 
PLGA microspheres. Nine volunteer patients suffering diffuse macular edema were 
treated with the TA-microspheres. The efficacy of the formulation was compared to 
conventional TA injections. Interestingly, the eyes treated with TA microspheres 
showed marked decrease of retinal thickness as well as improved visual acuity for 12 
months.  
Currently, the increasing development of bioengineered products (peptide, proteins 
nucleic acids, etc.) potentially useful in the treatment of diseases in the posterior 
segment of the eye makes necessary the development of microparticulate systems able 
to administrate such molecules in a effective manner. This fact would open the door to 
new therapies resulting especially hopeful for the diseases currently without effective 
treatment. In that sense, for example, Andrieu-Soler et al. [102] developed PLGA 
microspheres loaded with a proteic neurotrophic factor (glial-cell-line-derived 
neurothropic factor; GDNF) prepared according to the W/O/W emulsion technique. The 
microparticles were able to control the protein release (10 ng/d) for three months 
according to in vitro studies and resulted efficient preventing the retinal degeneration in 
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a rd1 mouse model for 17 days. Thereafter, a glaucoma animal model (rats), based on 
IOP elevation (episcleral injection of hypertonic NaCl solution) was also used to test the 
efficacy of the PLGA microencapsulation of GDNF. With this objective, in a first work, 
Jiang et al [210] tested microparticles prepared by the W/O/W emulsion technique. The 
in vitro release, previously evaluated was of 35.4 ng/mg over 71 days [211]. Nine weeks 
after intravitreal injection of GDNF loaded microspheres in the animal models, a 
significant increase of the survival of retinal ganglion cells (RGCs) and their axons was 
demonstrated. Checa-Casalengua et al. [106] developed PLGA microparticles (20-40 
μm) loaded with an antioxidant (Vitamin E) and GDNF by using a microencapsulation 
method derived from the S/O/W emulsion technique. In this method the 
biotechnological product was suspended in the oil as a first step of the microspheres 
formation, maintaining the stability of the protein during and after the procedure. The 
microspheres prepared according to this methodology were able to release the protein in 
its bioactive form for more than 130 days. Afterwards, authors observed that a single 
injection of 0.025 mg of microspheres (0.64 ng GDNF) in the same animal model of 
glaucoma previously described (IOP elevation) were enough to promoted RCG survival 
of 72.7% eleven weeks after injection, in contrast to 36.6%, 30.6%, and 29.0% of RGC 
survival observed in eyes treated with GDNF in solution, vitamin E and blank 
microspheres respectively.  
 
2.3. Microparticles for periocular administration 
As mentioned earlier, the periocular administration arises as an interesting alternative 
route to avoid some of the side effects related with intravitreal injections. Microparticles 
administered by this route should be maintained in the periocular space for a long time 
in order to provide sustained drug levels and enhanced drug absorption into the 
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intraocular tissues. In this sense, Amrite and. Kompella [212] studied the effect of the 
particle size of the disposition of non-biodegradable nanoparticles (20 and 200 nm) and 
microparticles (2 µm) after their subconjunctival injection in rats. The authors observed 
that only the microparticles (2 µm) and nanoparticles (200 nm) were retained at the site 
of administration for at least 60 days because nanoparticles of smaller size were rapidly 
cleared by the systemic and lymphatic circulation [4]. 
The efficacy of microparticles in delivering drugs to the posterior ocular tissue via 
periocular routes have been demonstrated in several preclinical studies. Many 
interesting works are related with the periocular administration of microparticles loaded 
with anti-inflammatory agents. For example, Kompella and co-workers prepared PLA-
budesonide microparticles (3.60 ± 0.01 µm) and nanoparticles (345 ± 2 nm) using the 
solvent evaporation method from an O/W emulsion. PLA-budesonide microparticles 
(75µg of budesonide), nanoparticles (50 µg of budesonide) and budesonide solution (75 
µg) were subconjunctivally administered in rats. The ocular tissues (retina, vitreous, 
lens and cornea) levels were compared at different times. On day 1, drug levels in the 
solution and nanoparticles groups were higher in all tissues evaluated, when compared 
with the group receiving microparticles. On the other hand, on days 7 and 14, drug 
levels in the microparticles group were higher in comparison with the solution and 
nanoparticles groups. Thus, subconjunctivally administration biodegradable 
microparticles were found to be useful in sustained retinal drug delivery [213]. The 
potential usefulness of subconjunctival injection of celecoxib-microparticles in treating 
diabetes-induced retinal abnormalities was studied by Ayalasomayajula and Kompella. 
Celecoxib-microparticles (3.9 ± 0.6 µm) were prepared by the solvent evaporation 
method using PLGA 85:15. Microparticles (containing 75 µg of celecoxib) were 
administrated by subconjunctival injection in a rat model of diabetes-induced retinal 
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oxidative stress. Results showed that microparticles were able to release the drug in a 
sustained way during 14 days in different tissues (retina, vitreous, lens and cornea). 
Furthermore, the diabetes –induces biochemical markers thiobarbituric acid reactive 
substances and 4-hydroxynonenal were significantly reduced. Microparticles also 
slightly inhibited the gluthatione (GSH) depletion and the increase in GSSG/GSH [214]. 
In other work, sterilized celecoxib-microparticles (dose 750 µg of celecoxib) were 
administrated by subconjunctival injection in a streptozotocin diabetic rat model. At 2 
months after administration of celecoxib-microparticles, the drug levels could be 
quantified in sclera-choroid, retina, vitreous and cornea. Furthermore, the authors 
showed that a single injection of the microparticulate system was able to delay the 
development or progression of the early pathophysiological changes in the retina as a 
result of diabetes. These findings were demonstrated by the celecoxib-microparticles 
which significantly reduced the diabetes-induced elevations of prostaglandin E2 (PGE2) 
secretion, VEGF (vascular endothelial growth factor) protein, the vitreous-plasma 
protein ratio and blood-retinal barrier leakage without causing any damage to the retina 
[149]. 
Kimura et al. evaluated the effects of PLA microspheres loaded of adriamycin, a potent 
antimetabolic agent, to prevent post surgical fibrosis after glaucoma filtering surgery in 
rabbits. PLA-microparticles of adriamycin were prepared by the solvent evaporation 
method from an oil in oil emulsion (O/O). Adriamycin-microparticles (doses, 100 µg or 
200 µg) were subconjunctivally injected. Results showed that the intraocular pressure 
(IOP) in the eye treated with adriamycin microparticles (100 µg) was significantly 
lower than the IOP in control eyes from 7-12 days. This effect was more prominent in 
the eyes treated with adriamycin microparticles (200 µg), where the IOP was lower than 
control from 6-16 days. The duration of patent filtering bleb in the eyes treated with the 
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Adriamycin- loaded microparticles was longer compared with the control eyes [215]. 
Saishin et al. evaluated the subconjunctival injection of sterilized microspheres system 
to release PKC412, a kinase inhibitor, in a porcine model of laser-induced choroidal 
neovascularization (CNV). PKC412-microspheres were prepared from an O/W 
emulsion using PLGA/glucose as biodegradable polymer. Subconjunctival injection of 
PKC412-microparticles (25% and 50% of PKC412, approximately) caused significant 
suppression of the CNV development at rupture sites in Bruch’s membrane in pigs. In 
these experiments authors also evaluated PKC412 levels in different ocular tissues, 
showing that twenty days after injection of 50% PKC412 microparticles, drug levels 
were detectable in vitreous, retina and choroid [190].  
Microspheres loaded with bioengineered products have also been administered by the 
periocular route. Gomes do Santos et al (2006) prepared nanosized complexes of 
antisense TGF-β2 phosphorothioate oligonucleotides (PS-ODN) with and without 
polyethylenimine (PEI) encapsulated in PLGA microspheres (“trojan” microspheres) 
using a solvent evaporation method from a double emulsion (W/O/W). A volume of 100 
µl of a suspension of 4-5 mg of microparticles (550 ng PS-ODN) in sodium hyaluronate 
1.35% were administered by subconjunctival injection in a rabbit experimental model of 
filtering glaucoma surgery. Results showed a significant increase in the intracellular 
penetration of ODN in conjunctival cells and demonstrated a 100% bleb survival. The 
subconjunctival injection prevented post-surgical fibrosis following trabeculectomy for 
42 days. [216]. Other example is the use of PLGA microspheres loaded with anti-
vascular endothelial growth factor (anti-VEGF) RNA aptamer to reduce the formation 
of new blood vessels in the eye [217]. The microparticles were able to deliver the 
aptamer in a sustained manner (average rate of 2 µg/d). The released aptamer retained 
its bioactivity, according to its antiangiogenic effect in human umbilical vein 
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endothelial cells (HUVECs). After in vitro permeation study it was observed that 
microparticles were able to release the aptamer through the sclera for a period of 6 days. 
Not only subconjunctival, but other periocular routes have been also evaluated. 
Interesting results have been obtained by administering drug-loaded microparticles in 
the sub-tenon virtual space. In our research group, Barbosa-Alfaro and co-workers [189] 
prepared Dx-loaded PLGA microspheres (Figure 4) for periocular administration that 
allowed the Dx in vitro released for 9 weeks. Five mg of Dx-loaded microspheres (828 
µg Dx) were administered by sub-tenon injection in rabbits’ eyes. Two weeks after 
injections Dx reached peak concentrations of 579.0 ng/g, 1749.6 ng/g and 69.2 ng/ml in 
choroid-RPE, retina and vitreous respectively.  
Sub-tenon injection has been even evaluated in humans. In a relevant work carried out 
by Panganelli and co-workers, it was reported that the sub-tenon injection of a 
combination of microspheres loaded with ciprofloxacin hydrochloride (2.0 mg) with a 
solution of 25 mg of TA were able to prevent the ocular inflammation and infection 
after cataract surgery. Ciprofloxacin microspheres (mean size 1.07±0.35 μm) were 
prepared with a spray-drying using PLGA 50:50. Authors compared the combined 
treatment (ciprofloxacin microspheres and TA) with topical administration of 
prednisolone (1%) and ciprofloxacin (3%) eye drops during 28 days. Both treatments 
were evaluated in terms of efficacy (anterior chamber cell and flare, conjunctival 
erythema, ciliary flush or symptoms of ocular inflammation) and safety (intraocular 
pressure, biomicroscopy and ophthalmoscopic findings). Results demonstrated that a 
single periocular injection had same therapeutic response and ocular tolerance as 
continuous administration of eye drops in controlling inflammations after cataract 
surgery [101].  
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3. NANOPARTICLES FOR OPHTHALMIC ADMINISTRATION 
The ability of nanoparticles to control the release of the loaded drug is very limited, due 
to its high surface area. However, the attractiveness of nanoparticles for ocular drug 
delivery is focused on two main aspects. The first one is their capacity to intimately 
interact with tissues, due to its reduced size. This characteristic makes nanoparticles 
excellent candidates to increase the retention time of the loaded drugs on the ocular 
surface. Similarly, nanoparticles can also develop intimate contact and can be 
phagocyted by other ocular tissues such as RPE cells, which results very suitable as 
targeting systems. Secondly, when nanoparticles are designed for other ophthalmic 
administration routes (periocular, intraocular), they resulted optimal systems to protect 
labile molecules against the external environment, increasing their half-life.  
 
3.1. Nanoparticles for topical administration  
As previously explained, the penetration of drugs through the cornea to the anterior 
segment structures present some limitations that could be partially solved with the use 
of nanoparticulate systems, since they offer the possibility to enhance the delivery and 
transport of drugs across these tissues. One of the first studies with NPs administered 
topically was made 25 years ago. In that study, PACA NPs loaded with progesterone 
were prepared and applied to rabbit eyes, and the time profile of the drug in several 
ocular tissues was assessed [56]. The emulsion polymerization technique was chosen by 
the authors to prepare these NP, which gave an encapsulation efficiency of 99%. The 
study was designed to compare progesterone loaded NPs with a solution of drug without 
polymer (used as control). However, the release of the drug from NPs was not as 
effective as expected. They observed interactions between drug and polymer that made 
progesterone less available for penetration on the precorneal area.  
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Nowadays it is possible to find studies with promising results with materials like PLA, 
PLGA, CNS or albumin.  
PLGA NPs were prepared by the nanoprecipitation technique to encapsulate 
flurbiprofen as antiinfammatory agent in ocular surgery[218]. NPs’ size ranged between 
232 and 277 nm and gave an encapsulation efficiency of nearly 95%. According to the 
authors, formulations did not show toxicity on the tissues and demonstrated to be more 
effective than sodium arachidonate (anti-inflammatory reference drug) after topical 
instillation in the rabbit eye.  
CNS is one the most promising polymers in the development of NPs for topical drug 
delivery. De Campos et al studied CNS NPs, prepared by the ionic gelation technique 
loaded with the hydrophobic peptide Cyclosporine A (CyA). The topical administration 
of this peptide has been used in a variety of ocular surface phenomena as dry eye 
syndrome, vernal conjunctivitis and corneal allograft rejection. CyA presents very low 
aqueous solubility, and it has been the object of numerous work looking to novel trends 
for topical administration [219]. These authors determined whether the ophthalmic 
administration of CyA could be improved by interactions of NPs with corneal and/or 
conjunctival tissues. A CyA suspension in chitosan was used as control. The mean 
particle size of NPs was around 300 nm and the drug loading values were around 9%. 
Animals treated with CyA-NPs had higher drug levels in cornea and conjunctiva than 
those treated with control, with a maximum at 2 hours post-administration. Therapeutic 
levels were found at least during 24 hours post-administration in conjunctiva, and 48 
hours in cornea. Brimonidine tartrate, an alpha-2 agonist ocular hypotensive drug with 
neuroprotective action, was also encapsulated in CNS NPs prepared by the ionic 
gelation technique [220]. The in vitro release study showed sustained release over 4 
hours in PBS (pH 7.4) and the in vivo experiments showed a significant sustained effect 
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of NPs in comparison with conventional brimonidine eye drops. A mixture of CNS and 
Carbopol® was used to elaborate NPs loaded with the miotic agent pilocarpine [221]. 
The incorporation of Carbopol® also contributed to the mucoadhesive properties of the 
formulation. In vitro release tests were compared with those obtained with a pilocarpine 
solution, a gel and liposomes. In all cases, the best slow-release profile of pilocarpine 
occurred with nanoparticles. Moreover, in the in vivo miotic study, NPs formulations 
showed the most significant long-lasting decrease in the pupil diameters of the rabbits. 
Other mucoadhesive agent, hyaluronic acid, was also combine to CNS to produce 
bioadhesive NPs intended for the administration of two hypotensive agents, 
dorzolamide and timolol [222]. After in vivo administration of these formulations in 
albino rabbits it was demonstrated that the combination of both bioadhesive polymers 
resulted very efficient at reducing IOP in comparison with a solution of the drugs at the 
same concentration. 
Other approaches have also been done with ACV pro-drugs encapsulated in PLGA NPs 
(160-190 nm) dispersed in a thermosensitive gel (PLGA-PEG-PLGA). The formulation 
remained liquid at room temperature and formed a gel at eye temperature after topical 
administration. This strategy allowed the formation of a depot in the eye surface that 
prevented the fast drainage of NPs, the interaction of pro-drugs with tear proteins, tear 
dilution of pro-drugs and pro-drug metabolism. The in vitro pro-drug release from NPs 
in buffer (40 mg in 1 ml PBS) exhibited a biphasic pattern with an initial burst release. 
This initial release was reduced when NPs were suspended in the thermosensitive 
vehicle. In the thermosensitive gel, NPs also showed a longer release in comparison 
with control (NPs without thermosensitive gel; 6 days versus 3 days) [223]. 
Cationic nanoparticles have been also tested as transfection agents. For example, Konat 
et al. described the transfection of a new plasmid designed to encode the human gel-
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forming mucin MUC5AC, whose expression is usually decreased in ocular surface 
alterations such as the dry eye syndrome. The plasmid was entrapped in hybrid 
cationized gelatin NPs produced by the ionic gelation technique (diameter smaller than 
150 nm; zeta potential between +20 and +30 mV; plasmid association higher than 90%) 
[224]. Transfection studies were made in a conjunctival and a corneal epithelial cell 
lines grown at a final confluence of 75%. Cells were incubated with the NPs for 3 hours 
(5 µg of plasmid/well). As controls, authors used naked plasmid associated with a 
commercial transfected agent (JetPEI-RGD). The formulations produced an efficient 
transfection of MUC5AC in both cells lines, however only the conjunctival cell line was 
able to express MUC5AC after NPs transfection. These results were corroborated after 
in vivo administration in rabbits, where it was observed that the treatment with NPs 
significantly increased the MUC5AC expression in the conjunctiva.  
SLNPs’ efficacy as topical drug delivery systems has also been studied recently with 
different active substances. Baicalin-loaded SLNPs[225], an anti-inflammatory and 
analgesic agent, were prepared following the emulsification/ultrasonication method 
(average diameter of 91.42 ± 1.02 nm and encapsulation efficiency around 63%). In the 
permeation studies made in excised rabbit corneas, results demonstrated that the system 
was able to enhance the corneal penetration of the drug in comparison with a baicalin 
solution used as control. The in vivo evaluation of tobramycin-loaded SLNPs (100 nm) 
administered on the corneal surface in rabbit eyes, showed a significantly higher 
bioavailability of the drug in the aqueous humor in comparison with an equal dose of a 
tobramycin solution [226]. The ocular delivery of acyclovir was also enhanced by 
incorporating it into SLNPs (400-777 nm), having a faster permeation through excised 
rabbit cornea [227]. Additionally, SLNPs have been loaded with methazolamide, an 
antiglaucoma active agent, showing a higher therapeutic efficacy and more prolonged 
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effect than a drug solution and a commercial formulation[228]. Another anti-glaucoma 
drug, timolol maleate, was encapsulated in SLNPs (160 nm) showing similar results 
[229]. Similarly, the in vivo efficacy of CyA was enhanced with its incorporation in 
these systems[230]. Furthermore, non-viral vectors based on SLNPs have also been 
studied in gene therapy for the treatment of ocular diseases. Delgado al co-workers 
tested the transfection efficacy of SLNP formulations in rat eyes by monitoring the 
expression of enhanced fluorescent protein (EGFP) after intravitreal, subretinal and 
topical administration. Depending on the administration route, the expression of EGFP 
was detected in different types of cells, even after topical application of the system 
[231]. 
 
3.2. Nanoparticles for intraocular administration  
As it was already commented, NPs have been evaluated after intravitreal and subretinal 
administration.  
The encapsulation of AG1478, an epidermal growth factor receptor and tyrosine kinase 
inhibitor, which is able to promote optic nerve regeneration, was evaluated by Robinson 
et al recently. Intravitreal injections (5 µl) of AG1478 loaded-PLGA NPs (359 ± 54 nm; 
50 mg MPs/ml) were evaluated in a rat optic nerve crush injury model. Four weeks after 
the injection, authors were able to detect NPs in the vitreous and could find fiber growth 
through the injury site [232]. In other study, the molecule tetra-iodothyroacetic acid, 
able to block angiogenic action over VEGF and erythropoietin, was encapsulated in 
PLGA NPs. The effect of the intravitreal injection of this system (75 ng) was evaluated 
in mice. While the administration of the drug alone had no statistically significant effect 
on retinal neovascularization compared with the vehicle, the administration of a single 
injection of loaded-NPs significantly reduced retinal neovascularization by 30.9% three 
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days after injection [233]. The effect of nanoparticle-mediated gene delivery of 
angiogenic inhibitors on retinal inflammation, vascular leakage and neovascularization, 
has also been studied in a diabetic retinopathy rat model. An expression plasmid of 
plasminogen kringle (K5), a natural angiogenic inhibitor, was encapsulated in 
PLGA:CNS NPs (260 ± 30 nm, plasmid loading of 11 ± 1.4 µg/ml) by the emulsion-
evaporation technique. K5-NPs were injected into the vitreous (8.8 µg/eye) and results 
showed that, for at least four weeks, K5-NPs attenuated vascular endothelial growth 
factor and reduced leukostasis and vascular leakage in the rat model used [234]. 
Advances have been already performed in the subretinal administration of NPs. Farjo et 
al. determined the efficiency of compacted DNA NPs to transfer a plasmid which 
encoded a green fluorescent protein (EGFP). NPs (4 mg/ml of DNA in saline solution) 
were administered by subretinal injection (1 µl) in mice. 2 days post-injection the 
examination of the tissues showed a fluorescent signal in the inner plexiform layer and 
in retinal ganglion cells. Substantial EGFP fluorescence was also detected in the lens, 
cornea and trabecular meshwork with no evidence of cellular infiltration or 
inflammation [235]. Hayashi et al (2009) determined the workability of subretinal 
delivery of goat immunoglobulin G (IgG) electrostatically adsorbed onto gold NPs in a 
model of retinal degeneration in rabbits. Results showed that, one month after the 
injection, IgG-loaded NPs could be still detected and located in the outer segments of 
the retina [236]. Other authors studied the therapeutic efficacy and safety of compacted 
DNA-NPs gene delivery into the subretinal space of a juvenile mouse model of retinitis 
pigmentosa. Rod function was measured by electroretinography showing a modest but 
statistically significant improvement compared with controls after injections [237]. Cai 
et al determined the utility of small NPs (diameter < 8 nm) composed of a therapeutic 
gen in a mouse model of retinitis pigmentosa with a phenotype of slow retinal 
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degeneration (rds). In this work, NPs were compacted by a peptide with a high 
transfectivity activity (CK30PEG, a PEG substituted 30-mer lysine peptide). Authors 
injected 0.3 µl of a suspension of NPs in saline solution (3.06 µg/ml) into the subretinal 
space in the superior temporal quadrant of the animals. As controls, saline solution and 
uncompacted plasmid DNA carrying the same therapeutic transgene, were used. The 
efficacy of the system was evaluated in terms of its ability to rescue the disease 
phenotype in the rds model, measuring the levels of several photoreceptor-specific 
proteins typically reduced in this animal model. Subretinal delivery of NPs transfected 
nearly all of the photoreceptor population and did not produce irreversible defects in 
retinal function. Interestingly, NPs were able to generate a cone function restoration to 
almost normal levels and a rod function improvement[139]. 
 
3.3. Nanoparticles for periocular administration  
The effectiveness of NPs by periocular administration for sustained transcleral drug 
delivery to the retina is highly limited by their size. As mentioned previously, it seems 
like only larger NPs (200 nm and above) are appropriate carriers, due to the fact that 
smaller NPs (20 nm or less) are washed very fast by the systemic or lymphatic 
circulation [238]. The clearance that takes place with larger NPs is mainly produced by 
retention and degradation at the site of administration, until NPs reach a size that is 
small enough for entry into the systemic or lymphatic circulation[239].  
Efficacy studies of NPs administered via periocular injection have been published. The 
effect of subconjunctivally administered budesonide NPs has been evaluated in 
Sprague-Sawley rats[240]. Budesonide loaded NPs were prepared with polylactide 
polymer by a solvent evaporation technique (345 nm, encapsulation efficiency of 65%) 
and were injected into the subconjuntival space with a 27G needle (50 µg 
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NPs/injection). A budesonide solution was used as control. Drug levels in retina and 
other tissues were determined at 1, 3, 7 and 14 days post-injection. At the end of day 7, 
budesonide concentration in cornea and vitreous was higher in the NP-treated group 
than in animals that received the budesonide control solution. On day 14, drug levels 
were below limits for both solution and budesonide NPs groups in all the tissues 
analyzed.  
 
4. LIPOSOMES FOR OPHTHALMIC ADMINISTRATION 
Liposomes are a very interesting strategy to increase the bioavailability of drugs in 
ophthalmology. They exhibit excellent ocular tolerance and can be used to entrap both 
hydrophilic and hydrophobic drugs with high efficiency, being also useful in gene 
therapy. They can be easily coated with different polymers conferring additional 
characteristics to the systems. However liposomes present limitations concerning 
sterilization and stability, which partially restrain their use. 
 
4.1. Liposomes for topical administration 
Liposome preparations to treat anterior segment disorders are designed to increase the 
drug residence time and enhance transcorneal permeation. As already mentioned, in the 
preparation of liposome-based formulation the lipid selection plays a fundamental role. 
Cationic liposomes, which are composed by molecules with positive charge as dioleoyl-
3-trimethyleammonium propane chloride (DOTAP) or stearylamine (SA) [172,241], 
seem to interact with the negatively charged mucins present at the corneal surface [242]. 
Several authors noticed that positively-charged liposomes produced an increase in 
residence time and, subsequently an increase in the drug bioavailability. For example, 
Schaeffer et al. prepared positively charged liposomes composed by PC, Cht and SA in 
  60 
a 7:2:1 molar ratio by thin-film hydration method to study the uptake by the cornea and 
the transcorneal drug flux. Authors observed that these positively-charged liposomes 
suffered statistically higher corneal uptake than neutral and anionic liposomes. In fact, 
penicillin G entrapped-positively unillamelar liposomes enhanced transcorneal flux 4-
fold in comparison with an equivalent concentration of free drug [175]. Law et al. also 
tested anionic and cationic liposomes to administrate ACV on the ocular surface. 
Positively-charged liposomes were constituted by PC from fresh egg yolk, Cht and SA 
and negatively charged liposomes were composed by PC, Cht and dicetylphosphate 
(DP) (1.6:1:0.15 molar ratio for both charged liposomal formulations). The drug-lipid 
hydration method was used to form ACV-liposomes that were then dispersed in a buffer 
solution (pH=7.4). In comparison with free ACV, cationic and anionic liposomes 
enhanced the bioavailability of the therapeutic agent as consequence of their intimate 
contact with the ocular surface that promoted an increase on the formulation residence 
time. Cationic liposomes presented higher ACV concentrations in the cornea than the 
anionic vesicles due to their electrostatic interaction with ocular mucins that allowed the 
formation of a completely coated layer on the ocular surface increasing the contact time. 
On its turn, although negatively charged liposomes were flexibly deposited on the 
corneal surface they were rapidly drained [20,243]. According to these findings, 
Saettone et al. compared a positively charged liposomal formulation (PC, Cht and SA) 
prepared by thin film hydration method following extrusion with a currently marketed 
ACV ointment. Liposomes (size 370.9±5.6 nm and ACV-loading 1.20 mg/ml) increased 
the drug concentration in the aqueous humor of New Zealand rabbits when compared 
with the ointment at the same ACV concentration [244]. These promising results 
promoted studies related to ocular pharmacokinetics and the delivery of active 
substance entrapped in liposomes to the vitreous humor by topical application. Tu et al. 
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prepared negatively charged GCV-loaded liposomes by the REV method (lipid 
components, PC:Cht:Na deoxycolate 12:1.7:1, wt:wt) . Liposomes were suspended in 
5% (wt:vol) sacharose solution obtaining (GCV final concentration of 1 mg/ml) and 
filtered by 0.22µm pore membranes. Liposomes resulted in a size of 200 nm, zeta 
potential was clearly negative (-52.5±6.8 mV) and encapsulation efficiency was close to 
52%. Although GCV liposomes and GCV solution presented similar precorneal 
clearance, probably due to the absence of any viscous agent, in vitro transcorneal 
studies of the GCV liposomes demonstrated a 3.9-fold higher permeability than that of 
GCV solution. GCV liposomes and GCV solution presented an aqueous humor 
concentration-time profiles described by 2-compartmental pharmacokinetics with first 
order transcorneal penetration and both dosage forms (liposomes and solution) allow 
GCV detection in aqueous humor, lens and vitreous. Liposomal preparation increased 
drug concentration by 2- to 10-fold in all these tissues (100-500 ng/g for GCV 
liposomes compared with 30-300 ng/g for GCV solution) [245]. 
Novel strategies directed to increase the retention time of the liposomal formulation at 
the site of action are focused on their combination with bioadhesive polymers. Although 
bioadhesive polymers can produce blurring vision at the moment of instillation [246], 
recently works show that when liposomes are suspended in hydrogels matrices, they 
increase the viscosity and residence time of the formulation, because of their adhesive 
nature, and can also prolong the drug release rate. [14].  
Budai et al. performed multillamelar vesicles encapsulating ciprofloxacin (CPX) by 
thin-lipid hydration method without posterior extrusion. Liposomes, composed by 
lecithin (LCT) or DPPC (extrusion was not performed), were suspended in different 
bioadhesive polymer solutions: a poly(vinyl alcohol) (PVA) solution 0.14% or 
polymethacrylic acid (PMA) 0.1% solution and were compared with PVA (0.14-15%) 
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and PMA (0,1-5%) CPX-containing gels. Release studies in PBS (pH 7.2) showed about 
60% and 80% of total CPX released after 300 min for LCT liposomes-PVA 0.14% and 
liposomes-PMA 0.1% combination respectively. Liposomes-PVA 0.14% increased 
release half-time from 72 min, values obtained for hydrogels prepared at the same 
concentration but without liposomes, to 212 min for LCT vesicles and 644 min for 
DPPC vesicles. Authors observed that the polymers-liposomal formulations behave like 
concentrated (3-10%) hydrogels without liposomes. In addition, these authors noticed 
that lipid composition also determine drug profile release. The higher release rates 
observed for lecithin formulations, in comparison to DPPC formulations would be 
explained by the higher membrane fluidity and permeability (lower main phase 
transition temperature) offered by the saturated and unsaturated lipids composing LCT, 
in comparison to the more rigid DPPC. Authors pointed out that the presence of drugs 
dissolved in the lipid bilayer could modify this behaviour[247]. Hosny et al. also 
developed CPX-liposomes constituted by soy LCT and Cht at different molar ratios by 
REV technique [118]. The maximum encapsulation efficiency (EE) (73.04%±3.06%) 
was obtained for liposomes LCT:Cht 5:3 (molar ratio). Furthermore, the inclusion of 
SA in the molar ratio 5:3:1 (LCT:Cht:SA) resulted in a EE of 82.01%±0.52%. In order 
to get a prolonged release effect of the active substance, liposomes were coated with a 
high viscosity polymer, Carbopol® 940 [248-250] at 1.5%. This combination promoted 
an increment in the time needed to release the 75% of the dose from 2h for non-charged 
liposomes to 6 hours for cationic liposomes and 10 hours for Carbopol® coated 
liposomes. Moreover an increment in CPX transcorneal permeation of 5-folds and 3-
folds for coated and uncoated liposomes respectively were observed in comparison to 
drug solution [251]. Similar results were obtained by these authors when CPX was 
substituted by gatifloxacin [252]. Additionally, oxoflacin (0.3%) was also incorporated 
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in REV liposomes containing DPPC:Cht:SA (4:3:1 molar ratio) dispersed in a 
thermosensitive gel composed by chitosan and β-glycerophosphate salt (1.8% w/v and 
3.8% w/v respectively). The presence of this hydrogel increased the amount of drug 
permeated through the cornea in 7-fold in comparison to the drug aqueous solution at 
the same concentration. The good results obtained were partially attributed to the 
capacity of chitosan to interact with ocular mucins and also to open tight junctions of 
the epithelial cells promoting the transcorneal flux [253].  
Not only nanoparticles but also liposomes have been evaluated as potential strategy to 
increase the bioavailability of CyA. Milani et al. developed liposomes incorporating 
CyA for preventing graft rejection. Large unilamelar vesicles composed of PC and 
phosphatidylserine (PS) in a 7:3 molar ratio were prepared by dialysis of mixed lipid-
detergent micelles method [254]. Grafted animals divided into different groups received 
empty liposomes, CyA oily eye drops (olive oil) or CyA-liposomes five times a day, 
daily for 10 days. After treatment, a 77% rate of graft survival was obtained with the 
CyA-liposomes group while the rate was 37% for non-treated group and 45% for the 
olive oil CyA group [219,255]. Another technological strategy to increase CyA 
bioavailability is to include liposomes loaded with CyA in a collagen shields to achieve 
higher concentrations of the therapeutic agent in cornea, sclera, aqueous humor and 
vitreous [256]. This study showed that animals received CyA-liposomes dispersed in 
collagen shields had CyA concentration levels in aqueous humor higher than animals 
received CyA-liposomes or CyA eye drops.  
Liposomes have been also investigated for the topical delivery of intraocular pressure 
(IOP) lowering agents. Acetazolamide (ACZ) and pilocarpine HCl [257] are some 
examples of the exceptional behaviour of topical liposome based formulations for 
glaucoma treatment. El-Gazayerly et al. prepared REV liposomes composed by 
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PC:Cht:SA and PC:Cht:DP both in a 7:2:1 molar ratio containing ACZ. Unilamellar 
liposomes with a particle size in the range of 300-500 nm were obtained. In this study 
positively-charged liposomes had higher encapsulation efficiency (49.5±91.95%), 
compared to the negatively-charged liposomes (29.27 ±2.16%). Moreover, cationic 
liposomes remained longer on the ocular surface, promoting a more pronounced and 
sustained reduction in IOP New Zealand rabbits [258]. 
 
4.2. Liposomes for intraocular administration 
Current trends for liposomes directed to posterior segment are focused on targeting and 
protecting the active substance increasing the half-life and improving the therapeutic 
effect. Liposomes encapsulating molecules for intravitreal delivery can control and 
relatively prolong the release of the active substance in the site of action. Besides, 
liposomes protect fragile molecules, can improve drug stability in biologic fluids and 
can reduce retinal toxicity [259]. However, problems related to stability in biological 
fluids and storage which limited drug capacity, and difficulties in sterilization make the 
development of liposomal formulations difficult to perform. 
Several studies have demonstrated that drug-liposomes complexes diminish drug 
toxicity because of a limited amount of drug is in contact with tissues. According to this 
fact, some drugs characterized by its high toxicity in the site of action have been 
formulated as liposomal form. Amphotericin B (AmpB) is a clear example [260,261]. 
Barza et al. showed that AmpB liposomal formulation (SUVs) composed by 
PC:Cht:tocopherol succinate (5:3:1 molar ratio) produced less toxic effects than a 
AmpB marketed solution after a single intravitreal injection in healthy pigmented 
rabbits. According to that results, lesions as focal retina damage, retinal atrophy or 
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necrosis, typically associated to AmpB solution were not present in animals that 
received AmpB-liposomes [197]. 
A novel formulation based on a pro-drug of GCV, 1-O-hexadecylpropanediol-3-
phospho-ganciclovir (HDP-P-GCV), entrapped into liposomes was developed by 
Freeman et al. to CMV infection treatment. Liposomes were prepared by REV with a 
complex formula: HDP-P-GCV:DOPC:DOPG:Cht at a molar ratio of 12:48:10:30. Pro-
drug final concentration to intravitreal injection ranged from 0.2 mM to 2 mM. A single 
intravitreal injection of HDP-V-GCV-liposomes (0.2 mM) was able to protect the 
treated eyes against CMV retinitis for 4-6 weeks in the CMV retinitis animal model 
developed by the researchers. Authors claimed that this novel formulation could 
resulted very promising for retinitis treatment by intraocular injection [262]. 
There are several works employing liposomes to encapsulate DNA or RNA for gene 
therapy which are administered by intravitreal route [29].  
Some works have evaluated the efficacy of lipoplexes to retinal diseases treatment 
[30,31]. The first liposomal formulation for intravitreal injection marketed was 
Vitraven™ (Formivisen, Isis Pharmaceuticals, Carlsbad, CA) (approved by the FDA in 
1998). Vitraven™ is composed by liposomes encapsulating an antisense oligonucleotide 
to the treatment of Citomegalovirus retinitis in AIDS patients [263,264].  
In another work, liposomes containing DOTMA (N-[1-(2,3-dioleyloxy)propyl]-N,N,N-
trimethylammonium chloride):DOPE (Dioleoylphosphatidylethanolamine) in a molar 
ratio 1:1 and DOTMA:Cht (1:1 molar ratio) were prepared according to the thin layer 
method by Sasaki et al. After sonication and extrusion, to obtain homogeneous sizes for 
lipid vesicles, liposomes were incubated with the plasmid DNA (pDNA) combining in a 
molar ratio1:2 (pDNA:cationic liposome charge ratio). pDNA:DOTMA:Cht showed the 
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highest transfection efficiency in the ocular tissue compared to pDNA alone and other 
lipid composition formulations prepared [265]. 
After intravitreal injection, lipoplexes must overcome two important barriers. The first 
one is the high viscosity of the vitreous that not only avoid the lipoplexes diffusion to 
reach the site of action (neuronal retina or RPE) but also induce lipoplexes aggregation. 
Secondly, the presence of the polyanionic glycoaminoglycans in the vitreous can 
displace the DNA from the complex. Improvements on lipoplexes formulation are 
nowadays under study to minimize these problems, for example by using pegylated 
lipoplexes. As example, Peeters et al. developed pegylated lipoplexes composed by 
DOTAP:DOPE (1:1 molar ratio) and DSPE-PEG from 0 to 16.7% by thin lipid 
hydration method. Liposomes size range from 233±12 nm to 106±5 nm decreasing size 
when increasing PEG and zeta potential ranged from 39±1 mV to 0±1 mV decreasing 
charge when increasing PEG. This study concludes that a concentration as 16.7% of 
DSPE-PEG in lipoplexes can avoid aggregation phenomena in the vitreous promoting 
transport of lipoplexes to the RPE [266]. Bochot et al. (2002) also developed pegylated 
liposomes for the intravitreal delivery of an oligonucleotide model, pdT16. The 
liposomes, composed of PC:Cht:PEG-DSEP (polyethylene glycol-distearoyl 
ethylphosphocholine) 64:30:6 molar ratio, were prepared by organic solvent 
evaporation method following cascade extrusion. The liposomal suspension was 
incubated with the oligonucleotide and 10 cycles of freeze-thaw were carried out to 
obtain the liposomal formulation containing pdT16 (250 µM) with a vesicle size of 150 
nm and an encapsulation efficiency of 17.7%± 6 4.7%. Intravitreal injection of 
liposomes loaded with oligonucleotide were able to protect the active substance against 
degradation and, besides, liposomes prolonged the pdT16 release into the vitreous, 
retina and choroid [267]. Lajavardi et al. (2009) also used pegylated liposomes to 
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improved intravitreal delivery of a proteic substance, VIP (vasointestinal peptide) for 
the treatment of uveitis inflammation. Labelled Rhodamine liposomes composed by 
PC:PG:Cht:PEG-DSPE:PE-Rh (final molar ratio 47:10:35:5:3) (final lipid concentration 
50 mM) were prepared by thin-layer method followed by extrusion and VIP was 
encapsulated by freeze-thaw method (150 µM) which lead in liposomes sizes in the 
range from 300 nm to 600 nm with a negative zeta potential. These mentioned 
liposomes, were able to protect protein from degradation in the vitreous, being 
dispersed in a hyaluronic acid matrix (1.2%) in order to maintain a sustained release of 
VIP [268]. Based on previous studies developed by Bochot et al., Camelo et al. 
determined the intraocular and biodistribution of Rhodamine liposomes (Rh-Lip) empty 
and loaded with Vasointestinal peptide (VIP) (VIP-Rh-Lip) 24h following intravitreal 
injection into healthy rats and, besides, authors evaluated the cells and organs 
implicated in the internalization of both liposomal preparations (unloaded and VIP 
loaded). Rh-Lip was prepared by thin layer method (composition and final molar ratio 
were PC:PG:Chol:PEG-DSPE:PE-Rh and 47:10:35:5:3 respectively). VIP was 
entrapped in Rh-Lip by freeze-thaw method (final VIP concentration in VIP-Rh-Lip 
was 0.55 mg/ml). After intravitreal injection of both liposomal formulations, liposomes 
stayed mainly in the posterior segment of the eye and some liposomes were internalized 
by retinal Müller glial cells. After VPI-Rd-Lip intravitreal injection, VIP was detected 
in macrophages and T cells indicating that VIP-liposomal formulation may be involved 
in regulating immune response in the eye [269].  
 
4.3. Liposomes for periocular administration 
Liposomes loaded with antigens had been proposed as periocular vaccines. Previous 
studies have demonstrated the main role of periocular vaccination for preventing HSV 
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infection in rabbits[270-273]. According to these results, Cortesi et al. developed 
positively-charged liposomes composed by PC:Cht:DDBA18 (dioctadecyl-dimethyl-
ammonium bromide), in a 8:8:1 molar ratio, and incorporated a recombinant secreted 
form HSV-1 glycoprotein B(gB1s) with a protective immunity activity and two peptides 
mimicking gB1s, DTK1 and DTK2, with additional antiherpetic activity. Liposomes 
were prepared by thin-lipid evaporation method and sonicated to obtain a homogeneous 
size. The final liposomal formulation was left maturate overnight to increases 
encapsulation efficiency. Liposomes presented a size close to 300 nm and a zeta 
potential about 23 mV. For in vivo evaluation, New Zealand rabbits were vaccinated by 
periocular administration (3 vaccinates for 3 weeks) with liposomes entrapping DTKs, 
liposomes including gB1s and empty liposomes. Afterwards, animals were infected 
with pathogenic HSV-1 variant and clinical eye signs and symptoms (conjunctivitis, 
iritis, epithelial keratitis, and corneal clouding) were evaluated on day 3,5,7,10 and 14 
post-infection. 6 of 9 animals treated with liposomal formulation containing both 
peptides and gB1s, survived compared to 0 survivals in animals vaccinated with empty 
liposomes. It was demonstrated that the liposomal formulations prepared increased the 
survival of HSV infected animals [246] 
 
5. MICROEMULSIONS AND NIOSOMES FOR OPHTHALMIC 
ADMINISTRATION 
5.1. Microemulsions for topical administration 
ME allow drug delivery and drug permeation across the ocular surface. Several authors 
have developed microemulsions for topical administration to solubilize drugs and to 
increase its ophthalmic bioavailability. Depending on the charge and the viscosity of the 
ME, the ocular contact time of the formulation can be increased. 
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CyA is an example of a drug incorporated in a ME. Restasis™ (Allergan, Inc., Irvine, 
California) is the first ME commercialized containing CyA 0.05% as ophthalmic 
formulation. Restasis contains polysorbate 80 and carbomer 1342 at alkali pH to 
stabilize the CyA -loaded anionic lipid emulsion. Several studies support a safety and 
favorable profile for CyA 0.05% in ophthalmic emulsion (marketed formulation) for 
ocular diseases as severe dry eye and meibomian gland dysfunction [274,275].  
Fialho et al. formulated dexamethasone in a ME elaborated by titration method in which 
dexamethasone was dispersed in the oily phase, composed by isopropylmiristate. After 
that, surfactant (Gremophor EL, a castor oil derivative) and water were added and 
mixed to form an O/W emulsion.  Then, the co-surfactant, propylenglycol, was added 
and mixed until a transparent system (microemulsion) was found. This ME presented 
suitable properties for topical administration in terms of pH, surface tension and 
viscosity. The formulation resulted stable for a three months period of time. As 
expected, the ocular irritation test (a modified Drazie test) showed that this ME did not 
produce significant alterations. The most interesting data are related to the 
bioavailability of the drug. 10 minutes after dexamethasone-microemulsion instillation, 
drug concentrations were found in the aqueous humor which also were detectable 480 
minutes after topical administration, compared with a commercialized dexamethasone 
ophthalmic suspension which was not detectable in the aqueous humor 360 min after 
instillation [276]. In this case the surfactants and co-surfactants act as penetration 
enhancers promoting the drug to cross the corneal barrier and the viscosity of the 
external phase (40.27 ±0.98 mPa·s) increased ME retention time onto the ocular 
surface. 
The surface charge of ME has been studied in order to increase the retention time onto 
the ocular surface and, subsequently, to achieve therapeutic drug levels in the anterior 
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and posterior segment of the eye. For example, Klang and co-workers (2000) 
formulated indomethacin in a positive-charged and in a negative-charged ME, and 
compared them with an indomethacin solution. Indomethacin ME components were: 
poloxamer and glycerol as non-ionic surfactant, the oily phase was composed by Lipoid 
80, a medium lipid chains composition, and α-tocopherol as antioxidant. To obtain 
positive and negative microemulsion were employed a cationic surfactant, stearylamine 
and an anionic lipid, deoxycholic acid, respectively. Indomethacin 0.1% was dissolved 
in the oily phase, and both phases (aqueous and oily) were heated separately to 70ºC, 
then heated together to 85ºC, and mixed using a high-shear Polytron® mixer. After 
cooling, emulsion was homogenized, filtrated by 0.45 µm and sterilization process by 
autoclave took place. The mean droplet size were 110 ± 37 nm and 164 ± 63 nm for 
positive and negative microemulsions respectively with no changes after sterilization 
process. Besides, indomethacin was chemically stable over a 24 months storage period. 
Positively charged emulsion enhanced drug corneal penetration achieving higher 
concentrations of indomethacin in aqueous humor and sclera-retina compared to 
solution and negatively-charged ME. In addition, positively-charged ME was well 
tolerated by animals with no irritation or inflammation after eight consecutive 
instillations hourly. The electrostatic effect between the positively-charged emulsion 
drops and negatively-charged cornea may be related with this high indomethacin 
bioavailability [277]. In this case, drug bioavailability increase in both, cationic and 
anionic formulations, explained by ME colloidal properties. Since the control 
formulation does not produce surface eye alterations so there is not an enhanced 
penetration effect and vehicle viscosity is not high enough to increase retention time (2 
cps). Nevertheless, the positively charged ME is able to interact with anionic epithelial 
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corneal surface increasing indomethacin bioavailability compared to both anionic ME 
and ophthalmic indomethacin suspension. 
Alany et al. evaluated the behaviour of phase-transition ME after instillation and 
posterior dilution with natural tears. Authors elaborated ME phase-transition systems 
with different viscosities incorporating a hydrophilic model drug, pilocarpine 
hydrochloride. ME phase-transition were comprised by two non-ionic surfactants, 
sorbitan mono laurate (Crill 1) and polyoxyethylene sorbitan mono-oleate (Crillet 4),  
the oily phase was ethyl oleate (Cromadol EO) and the aqueous phase was composed by 
water at different ratios. Water content affects the viscosity of each formulation, the 
higher the content of the aqueous phase, the higher the viscosity of the ophthalmic 
preparation. So, depending on the water concentration different systems were selected: 
w/o ME 5%, w/o ME 10%, liquid crystalline structure (LC) 26%, o/w coarse emulsion 
(EM) 85% and 100% solution (w/w). The oil:surfactant mixture weight ratios were kept 
constant with pilocarpine hydrochloride being incorporated at 1% (w/w). Finally, 
therapeutic efficacy was analyzed in terms of miotic response in male New Zealand 
rabbits. All tested preparations showed adequate surface tension to spread 
homogeneously over the cornea (34±1.6 dyn/cm). Regarding to rheological behaviour, 
LC structure resulted pseudoplastic (with an apparent viscosity of 5487 mPa·s) while 
the rest of formulations exhibit a Newtonian flow 112 and 167 mPa·s for 5% and 10% 
ME respectively). Pilocarpine in vitro release studies, performed in Franz diffusion 
cells, resulted dependent on the viscosity, and consequently on water content, so ME 
5% exhibited the faster release followed by ME 10% and finally LC. Regarding the 
miotic response, the colloidal formulation showed higher therapeutic efficacy in 
comparison with the solution, employed as control. The phase change in ME produces a 
viscosity increment and a flow behaviour change (from Newtonian to pseudoplastic). 
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Consequently, a magnification in ocular residence time and an increased drug 
bioavailability was observed [37,278]. 
The use of bioadhesive polymers in the aqueous phase of the ME demonstrated to 
enhance the drug bioavailability. In that sense, Chauhan et al. developed timolol ME in 
2-hydroxyethyl methacrylate (HEMA) gels to increase ocular residence time obtaining 
promising results [279].  
The feasibility of ME sterilization by gamma irradiation has been described by Bosela 
et al. These authors observed that 5% and 10% water content in ME can protect 
prednisolone from degradation during gamma irradiation at increasing doses of 2, 5, 10, 
15 and 20 KGy [159] 
 
5.2. Niosomes for topical administration 
Non-ionic surfactant vesicles (niosomes) have been present in the pharmaceutical field 
since the 80’s decade, their utility for ophthalmic drug delivery is being explored in the 
recent years because of their ability to increase ocular bioavailability 
Aggarwal et al., (2004) prepared niosomes to increase the ocular bioavailability of the 
poor soluble and permeable drug ACZ, employing sorbitan ester and cholesterol [40]. 
They evaluated different methods of preparation, being the REV method the best in 
terms of entrapment efficacy (43.75%). Authors included in the formulation DP or SA 
to obtain negatively and positively charged vesicles, respectively. They observed that 
although the positively charged niosomes offered the better entrapment efficiency and 
also a good corneal permeability, they resulted toxic for corneal cells. A bioadhesive 
niosomal formulation of AZC was also prepared by coating the niosomes with 
Carbopol®. The bioadhesive formulation resulted less toxic than positive niosomes. 
After instillation of 30 µl of the coated-niosomes suspension (0.5% ACZ), a comparable 
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physiological effect (intraocular pressure reduction) than a marketed eye drop 
formulation of dorzolamide 2% was observed, with the advantage of a 2-folds 
increment in the duration in comparison with the commercial formulation. These results 
were lately supported by pharmacokinetic studies using microdialysis [280]. It was 
observed that the niosomal formulation induced a more rapid penetration of the drug 
across the cornea. Furthermore the Cmax in the aqueous humor was two-folds increased 
and a significant broadening of peak from 80 to 120 min was also observed. In a similar 
study, these authors evaluated the use of niosomes coated with bioadhesive polymer 
such as Carbopol® and chitosan to increase the bioavailability of timolol maleate and 
compared them to timolol solution (0.25%) [41,281]. Authors observed that both 
coatings increased the antihypertensive effect of the drug. Among them, the chitosan-
coated niosomes offered a more sustained effect up to 8 h (versus 6 h for Carbopol®-
coated niosomes) and compared well with a timolol maleate 0.5% marketed gel 
formulation. It is interesting to remark that the niosome formulations showed less 
lowering of IOP in the contralateral eye (20-40% as compared to 100% in case of drug 
solution), indicating lesser systemic side effects. Abdelbary and El-gendy (2008) 
developed niosomes for the ophthalmic controlled delivery of a gentamicin sulphate by 
employing the thin film hydration technique[38]. They tested different commercial 
surfactants and included in the formulation cholesterol, as stabilizer, and dicetyl 
phosphate (DP) to get negatively charged surface niosomes. A preparation with 1:1:0.1 
molar ratio of polysorbate 60, cholesterol and DP gave the best EE values 
(92.02%±1.43) and release results, showing a release of 66.29±1.33% at 8 hours of 
release study. In this work no in vivo studies were performed to evaluate the efficacy of 
the formulations. Abdelkader and co-workers (2011) described the development and in 
vitro evaluation of Span 60-based niosomes for ocular delivery of naltrexone 
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hydrochloride (NTX) [39]. They also tested the incorporation of different additives 
demonstrating that these compounds can influence the entrapment efficacy and also the 
size and shape of niosomes. Ex vivo transcorneal permeation studies conducted using 
excised cow corneas showed that niosomes were capable of controlling NTX 
permeation and enhance its corneal permeability. The prepared niosomal formulations 
were found practically non-irritant when applied onto the surface of a 10-day-old hen’s 
chorioallantoic membrane [177]. The same authors observed that niosomal preparations 
were more viscous that drug NTX solution, suggesting better wetting and spreading 
abilities on the ocular surface. Interestingly, the prepared formulations were able to 
protect the encapsulated NTX from the photo-induced oxidation up to 3-folds in 
comparison to free NTX solutions [42]. 
 
6. DENDRIMERS FOR OPHTHALMIC ADMINISTRATION 
Despite all the attractive characteristics of dendrimers as new drug nanocarrier systems, 
their use in ophthalmic routes remains almost unexplored. In contrast to other 
administration routes (oral, intravenous or transdermic) where interesting progresses 
have been already performed [50,53,282] only a few authors have paid attention to the 
potential of dendrimers as drug carriers at ophthalmic level.  
 
6.1. Dendrimers for topical administration 
In the past years, some bioadhesive polymers have been tested to achieve higher 
residence time on ocular surface and decrease the frequency of administration in topical 
ophthalmic treatment [283]. In this sense, dendrimers contain high density of chemical 
groups on the surface that could interact with ocular surface tissues, increasing the 
loaded-drug retention time. An additional advantage offered by dendrimers is that they 
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do not provoke blurred vision nor formation of any veil on the corneal region, problems 
typically associated with other bioadhesive polymers [284]. In a pioneer work published 
in 2005, Vandamme and Brobeck designed a study to investigate the potential of 
PAMAM dendrimers as ophthalmic vehicles in ocular formulations [180]. They tested 
PAMAM dendrimers with peripheral carboxylic, amine and hydroxyl groups. No ocular 
irritation or watering reflex were observed in any of the dendrimers evaluated in 
concentrations up to 2.0% (w/v), after instillation of aqueous solution of dendrimers in 
eyes of New Zealand albino rabbits, even for the cationic ones, typically the worst 
tolerated in studies in other tissues [178,179]. Authors found that the mean ocular 
residence time for COOH- and OH- PAMAM dendrimers evaluated after their 
instillation in a buffer solution (approximately 4 to 5 hours), were comparable to that of 
the 0.2% w/v Carbopo1® solution, a well-known bioadhesive polymer for ophthalmic 
dosage forms. Interestingly, the residence time of PAMAM dendrimer with amino 
surface groups was even significantly longer than that of Carbopol® or HPMC solutions. 
Authors suggested that the bioadhesive properties of PAMAM dendrimers could be 
explained by their interaction with ocular mucins depending on the structure, shape, and 
surface functional groups. Pilocarpine nitrate and tropicamide were employed as model 
drugs for miotic and mydriatic activity tests on rabbits. During the evaluation of 
dendrimer-drug interaction, a host–guest relationship was suggested leading to a 
sustained release of both drugs. The activity results obtained showed that the co-
administration of PAMAM dendrimers with these drugs prolonged their 
pharmacological effect, indicating increased precorneal residence time, compared with 
solution of the drug in PBS. To profound on this aspect, in a recent work, our research 
group developed the first in vitro method based on biosensor chip technology (surface 
plasmon resonance) designed to evaluate the interfacial interaction phenomena between 
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human transmembrane ocular mucins and dendrimers. PAMAM dendrimers with NH2, 
OH and COOH terminal groups were tested and compared with linear polymers 
typically used in ophthalmic clinical practise to increase the drug retention time on the 
ocular surface (HA, carboximethyl cellulose -CMC- and HPMC). Results demonstrated 
a stronger tendency of PAMAM dendrimers whatever their surface chemical groups (64 
NH2; 64 COOH or 64 OH) to originate interfacial interaction with human ocular 
transmembrane mucins, in comparison to HA, CMC and HPMC, showing a relevant 
importance of the co-operative effect of dendrimer due to the proximity of the active 
chemical groups. Interestingly, the amino and hydroxyl terminal groups PAMAM 
dendrimers showed statistically similar tendency to interact with transmembrane ocular 
mucins, suggesting the high importance of non-ionic interactions at that level. The 
results obtained reinforce the usefulness of dendrimers as polymers able to increase the 
retention time of drugs on the ocular surface and hence their bioavailability [62]. 
Yao and co-workers published some works focused on the potential of PAMAM 
dendrimers as corneal penetration enhancement agents [285,286]. They prepared 
complexes of PAMAM dendrimers by hydrogen bonding interaction with puerarin, an 
isoflavone compound with ability to low the intraocular pressure. Both, cationic 
PAMAM dendrimers and anionic PAMAM dendrimers were tested. In vitro release 
studies demonstrated that the drug was slowly released from the complexes for several 
hours, especially for the cationic dendrimers (G4 and G5). The quantification of 
puerarin on rabbits’ tear after instillation of complexes in PBS (pH 7.4) showed longer 
ocular residence times for complex with mean values of elimination half-life of 1.01 
hour and 1.8 hours for complexes prepared with anionic and cationic PAMAM 
dendrimers respectively, in comparison to values of 0.8 hours observed for puerarin eye 
drops. Authors evaluated the corneal permeation enhancement activity of PAMAM 
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dendrimers using the Valia-Chien diffusion cell with excised rabbits corneas. An 
enhancing permeation behaviour of PAMAM dendrimers was observed probably due to 
their interaction with corneal epithelium membrane cells or originated by their ability to 
relax the epithelium cell junctions to increase the drug flux. This point was not clarified 
in the text.  
Not only PAMAM dendrimers but also new dendritic structures are being proposed 
specifically designed for ocular topic application. For example, Spataro and co-workers 
developed an interesting new series of phosphorus-containing dendrimers [287]. The 
core of the dendrimer was one quaternary ammonium salt and the terminal groups were 
carboxylic acids (3, 6 and 12 -COOH groups for G0, G1 and G2 respectively). 
According to authors’ suggestion, the presence of a quaternary ammonium group as 
core of dendrimers could replace benzalkonium chloride, so no preservative might be 
needed in the final formulation. Once synthetized and characterized, dendrimers were 
used to form electrostatic complexes with carteolol, an ocular anti-hypertensive drug 
used to reduce the intraocular pressure (IOP) in glaucoma treatment. The catanionic 
dendrimer created presented high water solubility only when the G0 dendrimer was 
used, while for G1 and G2 solubility limitations were found. Complexes were instilled 
in rabbits’ eyes to evaluate the benefit of these nanosystems to enhance the penetration 
of the drug to the aqueous humor. No irritation was observed, whatever the dendrimer 
used, for several hours. In spite of the low solubility of the conjugate prepared with the 
second generation of dendrimer, the quantity of carteolol penetrating inside the eye was 
larger (2.5 folds) than expected when compared with carteolol alone. Authors concluded 
that, even if the solubility of such systems is a limitation, the pharmacodynamic 
observations highlight the potential usefulness of phosphorous anionic dendrimers on 
the ocular surface. 
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In another interesting work, Durairaj and co-workers evaluated the use of dendrimeric 
polyguanidilyated translocators (DPTs), a novel class of dendrimers with triolyl 
branches and surface guanidine, as ophthalmic delivery nanocarrier of gatifloxacin for 
topical application in the treatment of bacterial conjunctivitis [288-290]. The model 
drug selected, gatifloxacin, was complexed with DPT dendrimers forming 
nanostructures (346 nm) thanks to ionic, no-ionic and hydrophobic interactions. 
According to authors, at these conditions the solubility of the drug was four-fold 
increased and its antibacterial activity against resistant strain of S. aureus was even 
enhanced. In a drug uptake in vitro study with corneal epithelial cells, it was observed 
that the complexes rapidly penetrated into the corneal cell in a few minutes, in 
comparison to drug alone. The drug-dendrimer nanosized complex was instilled in the 
eye of New Zealand rabbits at concentration 1.2% wt/vol. Results demonstrated that the 
complex of gatifloxacin with DPT dendrimers increased the bioavailability of the drug 
in targeted tissues in magnitude, with in 13-fold, and 2-fold higher areas under the curve 
(AUCs) for tissue concentrations in conjunctiva and cornea, respectively, when 
compared with drug solution. An increment in drug bioavailability in velocity was also 
denoted offering sustained aqueous humor and vitreous drug levels during the 24-hour 
study, with half-life values of 9 and 32 hours, respectively. Authors suggested that the 
systems created would allow the instillation of the drug in the complex only once a day 
to control the infection. 
 
6.2. Dendrimers for intravitreal administration 
Marano and co-workers have published several works concerning the use of cationic 
lipoaminoacids dendrimers to enhance cellular uptake of antisense-
oligodesoxinucleotides (AS-ODNs) after intravitreal injection. Firstly, Wimmer and co-
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workers designed and synthesized lipid–lysine dendrimers in an attempt to improve the 
delivery into the nuclei of retinal cells of ODN-1, a sense oligonucleotide that was 
reported to have potent anti-VEGF activity, potentially useful in the treatment of ocular 
disease such as ARMD and DR [291]. The new dendritic structure combined the 
presence of the lipidic part, with high degree of membrane-like character that might 
facilitates their crossing of biological membranes, and the poly-Lys part that could 
interact with ODN-1 offering protection of nucleic acids against nucleases. The 
transfection potential of the formed dendriplexes was confirmed in retinal pigmented 
epithelium cells (RPE D407) cultures. In a second work [292], authors increased the 
chemical family of lipid–lysine dendrimers and reported the ability of these lipid–lysine 
dendrimers to delivery ODN-1 into cells, causing a reduction in VEGF expression after 
intravitreous injection in choroidal neovascularisation (CNV) animal models (rats). The 
results showed that dendrimer/ODN-1 dendriplexes significantly suppressed VEGF 
expression in cell level studies during the first 24 hours (40–60%), some of them even 
remained active for up to 2 months after injection, verifying that these lipid–lysine 
dendrimers could protect the ODN-1 form nucleases and prolong its delivery in vivo. In 
a third study [293], the in vivo study was prolonged for six months, observing that the 
VEGF reduction remained active for four months. Furthermore, in that study authors 
also evaluated the dendriplex tolerance after in vivo administration. No significant 
toxicity and damage were observed on injected rat eyes after ophthalmological 
examinations. Finally, in 2006 a new family of lipid-lysine dendrimers were presented 
with galactose moieties on their surface [294]. Authors observed that this modification 
increased the solubility of the nanosystems and increased the transfection of 
oligonucleotides in RPE 51. However, they recognized that the chemistry of this new 
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family might be improved. Since then, to our knowledge, any new result has been 
published. 
In a recent work, Izze and co-workers showed that PAMAM dendrimers with OH 
terminal groups have an intrinsic ability to selectively localize microglia, and can 
deliver drugs inside these cells for a sustained period [295]. Studies with fluorescent 
markers attached to surface chemical groups of the dendrimer demonstrated that this 
tropism was only observed in the retina of rats with retinal degeneration. Authors 
hypothesised that in case of neuroinflammation, activated microglia, very phagocytic, 
could endocytose the dendrimer, retaining them during four weeks at the experimental 
conditions. According to authors, this pathology-dependent biodistribution could be 
exploited to treat disease promoting retinal neuroinflammation like age-related macular 
degeneration and retinitis pigmentosa. Authors prepared conjugates of PAMAM-OH G4 
with fluocinolone acetonide, a neuroantinflammatory drug. The conjugate released the 
drug in a sustained manner over 90 days. In vivo efficacy studies demonstrated that only 
one intravitreal injection (1 µg of drug/ 7 µg of dendrimer) was able to stop retinal 
degeneration, preserve photoreceptor outer nuclear cell counts, and attenuate activated 
microglia, for an entire month in a rat retinal degeneration model. 
 
6.3 Dendrimers for periocular administration 
Shaunak and co-workers evaluated the conjugation of anionic PAMAM dendrimers 
with glucosamine to prepare immuno-modulator systems and the conjugation with 
glucosamine 6-sulfate to obtain antiangiogenic systems. These two conjugates were 
administered by subconjunctival injection in a rabbit model of wound healing after 
glaucoma filtration surgery. Results showed that the co-administration of the two 
dendritic conjugated increased the long-term success of the surgery from 30% to 80%, 
reducing the inflammation and decreasing the angiogenic responses, compared to 
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placebo-treated animals. In addition, there was no evidence of any persistent 
inflammatory or neoangiogenic response 30 days post injection. Authors claimed the 
potential utility of the systems created in clinical practice [296]. 
Kang and co-workers [297] prepared host-guest anionic PAMAM-carboplatin systems 
that aggregates forming nanoparticles (258 nm). Authors proposed the administration of 
these nanoparticles by subconjunctival injection for the treatment of retinoblastoma, to 
reduce the important side effects connected to systemic or subconjunctival 
administration of drug solution. Results demonstrated that the mean tumour mass in 
eyes of retinoblastoma animal models (LH-Tag mice) was significantly reduced after 
injection of nanoparticles, in comparison to the non-treated group and also in 
comparison to the group treated with carboplastin aqueous solution. Authors explained 
the results on the basis of prolonged retention of nanoparticles and sustained drug 
delivery. 
 
7. CONCLUSIONS AND PERSPECTIVES 
The present review describes the usefulness of different pharmaceutical systems for 
ocular administration by different routes of administration. 
Depending on the target site topical, periocular and intravitreal administration is chosen. 
Tolerance is critical in all formulations as the ocular tissues are extremely sensitive. For 
topical administration, liquid and semisolid formulations are the most preferred. 
Although nanoparticles have demonstrated to increase bioavailability of the drug by 
their penetration to the cornea, especial care has to be taken in order to avoid alteration 
of this physiological barrier.   
One of the key challenges to effective ophthalmic therapy is to target the active 
substance to the specific ocular tissue. Liposomes, dendrimers and niosomes are 
promising mainly for topical administration. They can be used to augment penetration 
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of the active substance through the cornea and/or conjunctiva to reach the aqueous 
humor or anterior segment tissues and for diseases affecting the surface of the eye. 
Furthermore, their use in the ophthalmic field is not limited to drug delivery. In fact, 
liposomes are already proposed as components of artificial tears as their components are 
similar to the ones present in the preocular tear film.  
Nano and microparticulate systems play an important role in the future of treatment of 
ophthalmic diseases affecting the back of the eye. It is clear that microparticles are more 
useful for the treatment of chronic diseases in which effective concentrations of the 
active substances have to be maintained during long periods of time. Nanoparticles are 
useful to protect substances for degradation and result more adequate to gen delivery 
and to be up taken by the RPE or other cells with phagocytic activity. 
A greater focus is being placed on the combination of different pharmaceutical systems 
to design personalized therapies. Future directions will be further developments of 
effective topical formulations involving more sophisticated physicochemical systems 
(i.e. liposomes and niosomes dispersed in bioadhesive, or thermo-responsible polymers, 
ME with the addition of bioadhesive polymer). Dendrimers are promising platform for 
ophthalmic therapy as the functional groups on their surface can be readily controlled 
for enhancing cell permeability, targeting or drug delivery. Advances in nanotechnology 
will provide innovative nanoparticles useful for poor aqueous soluble, poor permeable 
or labile therapeutic molecules. Microparticles loaded with several active substances 
will allow the treatment of chronic and multifactorial ophthalmic diseases offering the 
advantage of more prolonged drug delivery compared to nanoparticles. 
On-going research is being conducted to determine the efficacy and safety of the new 
advantageous ophthalmic formulations. 
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FIGURES AND CAPTIONS 
Figure 1: General non-scaled schema of the main micro and nanosystems intended for 
ocular drug delivery. 
Figure 2: Different administration routes for ocular drug delivery. 
Figure 3: Elaboration of liposomes by the thin-layer hydration method 
Figure 4: Elaboration of PLGA microspheres loaded with dexamethasone by the O/W 
emulsion method 
Table 1: Classification of the lipid vesicles depending on their structure. 
Table 2: Main bibliography related to micro and nanosystems for administration. 
 
 
